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ABSTRACT 
 
 
Chlamydia trachomatis is an obligate intracellular bacterium that exhibits a 
unique biphasic developmental cycle that can be disrupted by growth in the presence of 
IFN-γ and β-lactams, giving rise to an abnormal growth state termed persistence.  
Relatively little is known about the regulatory mechanisms that control temporal gene 
expression during the developmental cycle or the control of persistence and reactivation.  
Here we have examined the expression of a newly defined family of non-coding RNAs 
(ncRNAs) that are differentially expressed during the developmental cycle and the 
induction of persistence and reactivation (Using IFN-γ and Carbenicillin).  Non-coding 
RNAs were initially identified using an intergenic tiling microarray and were confirmed 
by Northern blotting.  A group of 10 ncRNAs were mapped and characterized and 
compared to the previously described chlamydial ncRNAs (IhtA, pCHL antisense 
transcripts).  The 5’ and 3’ ends of the ncRNAs were determined using an RNA 
circularization procedure.  Promoter predictions indicated that all ncRNAs were 
expressed from σ66 promoters and 9 ncRNAs contained non-templated 3’ poly-A or poly-
AG additions. 
 
Expression of ncRNAs was studied by Northern blotting during i) the normal 
developmental cycle, ii) IFN-γ-induced persistence, and iii) carbenicillin-induced 
persistence.  Differential temporal expression during the developmental cycle was seen 
for all ncRNAs and distinct differences in expression were seen during IFN-γ and 
carbenicillin-induced persistence and reactivation.   
 
Two of the studied ncRNAs were cis acting antisense molecules (CTIG270 and 
CTIG153).  Expression of CTIG270 in a surrogate E. coli system along with its target 
gene ftsI proved that it was an antisense RNA, and it effectively controlled ftsI 
availability.  A screening system was developed to determine the targets of potential 
trans-acting ncRNAs.  The screen was composed of two compatible plasmids, a high 
copy effector plasmid expressing the ncRNA and a low/medium copy target plasmid 
expressing chlamydial library.  Target plasmid contained translational fusion between 
chlamydial library and a positive/negative selection fusion system (ccdB/CAT 
fusion/TEV protease).  The selection process to identify potential targets for ncRNAs was 
carried out over two stages.  Stage one was to eliminate self ligated plasmids and non 
translational fusions, in this phase, only CAT+ ccdB resistant cells survived 
chloramphenicol selection i.e. cells representing true translational fusions survived 
antibiotic selection.  Plasmids enriched for by stage one selection were subjected to stage 
two selection.  In stage two ccdB sensitive cells were double transformed with both target 
plasmid and effector plasmid.  Only in instances when ncRNA inhibits translation of 
ccdB would cells survive this selection.  Stage two selection enriched for target(s) of 
ncRNA under test.  We show in details the construction of this screening system and its 
functional aspect. 
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CHAPTER 1.   INTRODUCTION1
 
 
 
1.1 CHLAMYDIA 
 
The order Chlamydiales encompasses a large group of bacteria characterized by 
their obligate growth in eukaryotic cells.  The last decade has seen a rapid expansion of 
the number of organisms within the order, including organisms from numerous animal 
and environmental sources.  This has led to the proposed division of the family 
Chlamydiaceae to include two genera, Chlamydia and Chlamydophila and the inclusion 
of non-Chlamydiaceae such as Simkaniaceae, Waddliaceae and Parachlamydiaceae 
(Everett et al, 1999).  The taxonomy of the Chlamydiales is controversial at this time and 
many feel the genera divisions are unnecessary.  I have chosen to use the terminology 
described in Schachter et al, 2001 i.e. the use of a single genus, Chlamydia. 
 
Chlamydiaceae are the etiological agents of many important human and animal 
diseases.  In humans, the genital serovars of Chlamydia trachomatis (C. trachomatis) are 
the most prevalent cause of sexually transmitted disease worldwide (Gerbase et al, 1998), 
while the ocular serovars result in blinding trachoma in developing countries (Schachter, 
1978).  Chlamydia pneumoniae (C. pneumoniae) is a widespread respiratory pathogen 
(Kuo et al, 1995) and chronic infections are associated with an enhanced risk of 
developing atherosclerotic (Saikku et al, 1988 and Kuo et al, 1993), cerebrovascular 
(Balin et al, 1998), and chronic lung disease (Hahn et al, 1991).  Pathogenic chlamydial 
isolates have been characterized from a number of animal hosts including birds, cats, 
rodents, cattle and pigs (e.g. Meijer, 2002). 
 
Chlamydia alternates between two morphological forms, the elementary body 
(EB) and the reticulate body (RB) (Moulder, 1991).  EBs are extra-cellular, metabolically 
inert forms, responsible for dissemination of infection by their ability to attach to and 
invade susceptible cells.  Upon infection, EBs are internalized in membrane bound 
vacuoles termed inclusions.  EBs differentiate into metabolically active forms, termed 
RBs, and undergo repeated cycles of binary fission leading to secondary differentiation 
back to EBs.  The host cell then lyses, releasing EBs, which infect neighboring cells.  
Under stressful growth conditions, imposed by immunological responses, antibiotics, or 
nutrient deprivation, the developmental cycle is disrupted, resulting in the appearance of 
large, aberrant RBs (reviewed in Hogan et al, 2004).  This altered growth scheme appears 
to be associated with continued expression of genes associated with DNA replication but 
not with those genes involved with bacterial cell division (Belland et al, 2003a). 
 
 
 
 
 
                                                 
1 Adapted by permission.  Abdelrahman YM, Belland RJ (2005) The chlamydial developmental cycle.  
FEMS Microbiol Rev 29: 949-959. 
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1.2 THE DEVELOPMENTAL CYCLE 
 
 
1.2.1 ELEMENTARY BODY 
 
The term “elementary body” (EB) refers to the small (ca. 0.3 μm), round, electron 
dense, infectious form of the organism (e.g. Matsumoto, 1973and Eb et al, 1976).  EBs’ 
nucleotide is highly compacted due to the condensation of nuclear material by the 
bacterial histone-like proteins HctA and HctB (Barry et al, 1992 and Brickman et al, 
1993).  Chlamydial EBs are unusual in that little or no peptidoglycan is present in the cell 
wall.  Structural rigidity is thought instead to be due to the highly cross-linked nature of 
the outer-membrane complex.  Inter and intramolecular cystine bonds exist between the 
cysteine rich proteins of the outer envelope including OmpA, OmcB, and OmcA 
(reviewed in Hatch, 1999). 
 
Recent studies indicate the interaction of EBs with host cells occurs in a two-stage 
process.  The initial reversible attachment occurs through electrostatic interactions of the 
bacteria with heparan sulfate containing glycosaminoglycans (Su et al, 1996; Su and 
Caldwell, 1998; Stephens et al, 2001) and (Taraktchoglou et al, 2001); and a second, 
irreversible, binding stage (Carabeo and Hackstadt, 2001).  Clifton et al, 2004 have 
recently shown that, immediately following the irreversible binding step, a type III 
secretion system secretion system (TTSS) exported protein is delivered into the host cell.  
This protein, termed Tarp (Translocated actin-recruiting phosphoprotein, CT456), is 
rapidly phosphorylated at tyrosine residues and phosphorylation correlates spatially and 
temporally with actin recruitment (Figure  1-1). 
 
 
1.2.2 PRIMARY DIFFERENTIATION 
 
The chlamydial developmental cycle has a singular enigmatic stage, the 
differentiation of the infecting EB to a metabolically active RB.  The process of 
differentiation can be blocked by the addition of antibiotic inhibitors of transcription or 
translation, suggesting that de novo protein expression is required to begin intracellular 
growth (Scidmore et al, 1996).  This finding is at odds with the generally held 
understanding that the presence of the bacterial histone-like proteins HctA and HctB 
render the EB transcriptionally incompetent.  This paradox has been at least partially 
addressed by the findings of Grieshaber et al, 2004 chlamydial histone–DNA interactions 
are disrupted upon germination by a small metabolite in the non-mevalonate pathway 
(MEP) pathway of isoprenoid biosynthesis.  The metabolite is thought to be 2-C-
methylerythritol 2, 4-cyclodiphosphate and is involved in functional antagonism of HctA.  
Findings showed that an E. coli HctA expression system was rescued from the lethal 
effects of HctA by chlamydial ispE.  ispE is an intermediate enzyme in the MEP 
pathway, paradoxically; experimental data showed that E. coli orthologue of ispE could 
not protect E. coli from the lethal effects of HctA expression.   
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Figure  1-1  A schematic representation of the chlamydial developmental cycle.  The host 
cell cytoplasmic membrane (red line) is shown to depict the interactions of chlamydial 
EBs and the origin of the inclusion membrane.  The major events in the developmental 
cycle are categorized as described in the text to allow an overview of the processes and 
mechanisms associated with acute and persistent chlamydial growth.  TARP 
(Translocated Actin-Recruiting Phosphoprotein, CT456), TTSS (Type III Secretion 
System), MEP (non-Mevalonate Pathway), CPAF (Chlamydial Protease/proteasome-like 
Activity Factor). 
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The question arises whether it is special enzyme kinetics attributed to chlamydial 
IspE or the transcriptional activity of the chlamydial ispE in the presence of HctA, or 
another unknown function that chlamydial ispE has that helps in the rescue from HctA 
lethality.  Chlamydia possess another histone-like protein HctB, it is still unknown what 
antagonizes its function during the differentiation step (Grieshaber et al, 2004). 
 
Transcription begins within the differentiating RB almost immediately following 
internalization.  New protein expression can be detected within 15 min PI using intrinsic 
labeling procedures (Plaunt and Hatch, 1988) and newly synthesized RNA can be 
detected in “host-free” Chlamydia by 1 h PI (Crenshaw et al, 1990).  Wichlan and Hatch 
(Wichlan and Hatch, 1993) identified the first early gene (euo, Early Upstream open 
reading frames [ORF]) using “host-free” early RNA to select clones from a genomic 
library.  Transcription of euo was confirmed by Northern blotting and primer extension 
analysis.  Euo appears to be specific to Chlamydia in that it is highly conserved within 
the genus but has no homology to other bacterial proteins.  Despite its early 
identification, the function of Euo has not been clearly defined to date. 
 
Following the sequencing of the serovar D genome, a number of studies used RT-
PCR to identify genes expressed early in the cycle.  Shaw et al, 2000, identified a number 
of inclusion-associated protein genes (inc) as early genes and proposed the generally 
accepted temporal classes of developmentally expressed genes as (i) early (1–2 h PI), (ii) 
mid-cycle (3–18 h PI), (iii) late (20–48 h PI).  More recently, genome-wide DNA 
microarrays have been used to determine the transcriptome throughout the cycle.  Belland 
et al, 2003b identified 29 genes expressed by C. trachomatis serovar D at 1 h PI in HeLa 
229 cells.  Seven of these genes had been previously characterized as early genes, 
including the previously mentioned euo and inc genes. 
 
 
1.2.3  RETICULATE BODY 
 
The “reticulate body” (RB) arises from the internalized EB following primary 
differentiation, as discussed above.  RBs are larger than EBs (ca. 1 μm) and the 
cytoplasm appears granular with diffuse, fibrillar nucleic acids, in contrast with the 
highly condensed nucleic acid content of the EB (reviewed in Matsumoto, 2000).  RBs 
are non-infectious and are bounded by an inner and outer-membrane, resembling other, 
Gram-negative, eubacteria.  RBs undergo binary fission throughout the middle part of the 
developmental cycle. 
 
 
1.2.4 GENE EXPRESSION 
 
Microarray analyses of gene transcription during the developmental cycle have 
been reported for C. trachomatis serovar L2 (Nicholson et al, 2003) and serovar D 
(Belland et al, 2003b).  While a number of technical and experimental design differences 
were used for the analyses, both reports indicate that by 6–8 h PI the developing RBs 
were highly transcriptionally active.  Belland et al (2003b) classified temporal gene 
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expression groups into early, mid-cycle and late categories with a subgrouping of genes 
expressed at 1 h PI as immediate-early.  While this study focused on the immediate-early 
and late genes, the complete listing of transcriptional activities (Belland et al, 2003b) 
throughout the cycle indicated that the period of intense transcriptional activity (16–24 h 
PI) correlated with the rapid growth and division of RBs.  Furthermore, they reported that 
virtually every gene in the organism is expressed at some point in the cycle, indicating 
that C. trachomatis has virtually no facultative capacity, as might be expected for an 
obligate intracellular organism with a “minimal” genome. 
 
 
1.2.5 TYPE III SECRETION MACHINERY 
 
Genomic data reveals that all chlamydial species possess a complement of genes 
encoding TTSS (Stephens et al, 1998; Kalman et al, 1999) and (Read et al, 2000).  TTSS 
genes in Chlamydia show temporal regulation through out the developmental cycle 
(Fields and Hackstadt, 2000; Fields et al, 2003; Slepenkin et al, 2003). 
 
 
1.2.6  CELL DIVISION 
 
Cell division takes place during the RB stage.  Genome sequencing indicated that 
Chlamydia lack an identifiable ftsZ orthologue, which encodes a protein centrally 
involved in bacterial cell division and found in all other sequenced eubacteria.  Another 
surprising finding in the genomic analyses was the presence of a complete set of genes 
for the synthesis, assembly, and degradation of peptidoglycan (PG) (Chopra et al, 1998; 
Stephens et al, 1998; Read et al, 2000;) and (Read et al, 2003) Numerous studies had 
reported that Chlamydia lacked peptidoglycan, with a single study reporting trace 
amounts in EBs (Su H., 1985).  Similarly, attempts to identify peptidoglycan in RBs were 
unsuccessful (Barbour et al, 1982).  Somewhat surprisingly, the production of infectious 
EBs is highly sensitive to inhibitors of PG synthesis, including β-lactam antibiotics and 
D-cycloserine (Matsumoto and Manire, 1970; Tamura and Manire, 1968; Weiss, 1950).  
Treatment of infected cells with these agents inhibits cell division and leads to the 
formation of large, aberrant RB that cannot differentiate to EB (Moulder, 1993).  These 
studies indicate that chlamydial PG synthesis may be required for chlamydial cell 
division and proper differentiation.  This paradoxical situation has been referred to as the 
“chlamydial anomaly” (Ghuysen and Goffin, 1999).  McCoy et al, 2003 have shown that 
the chlamydial MurA orthologue (UDP-N-acetylglucosamine enopyruvyl transferase), 
which catalyzes the first committed step in peptidoglycan biosynthesis, is functional in E. 
coli.  The chlamydial MurA was found to encode a fosfomycin-resistant form of the 
enzyme and this resistance was imparted to E. coli expressing the chlamydial enzyme.  
Expression studies indicated that Chlamydia are naturally fosfomycin resistant and that 
murA is expressed at the point in the developmental cycle immediately preceding cell 
division (Belland et al, 2003b) and (McCoy et al, 2003), providing circumstantial 
evidence for the involvement of peptidoglycan synthesis in cell division.  Brown and 
Rockey (Brown and Rockey, 2000) have identified an antigen named the septum antigen 
(SEP antigen) localized to a ring-like structure at the apparent septum within dividing 
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chlamydial reticulate bodies (RB).  Antisera directed against SEP show similar patterns 
of antigen distribution in C. trachomatis and C. psittaci RB.  Treatment of chlamydiae 
with inhibitors of peptidoglycan synthesis or culture of chlamydiae in medium lacking 
tryptophan leads to the formation of nondividing, aberrant RB.  Staining of aberrant RB 
with anti-SEP reveals a marked redistribution of the antigen.  The reversal of aberrant 
formation results in the production of normal RB and a redistribution of SEP to the 
apparent plane of bacterial division. 
 
 
1.2.7 SECONDARY DIFFERENTIATION AND LATE GENE EXPRESSION 
 
Following the period of rapid cell division, RBs begin to redifferentiate to EBs, 
here termed “secondary differentiation”.  The signal for this process is unknown and 
efforts to identify quorum sensing type pathways are not been supported by genomic 
analyses. 
 
Expression of a number of late-cycle genes occurs during secondary 
differentiation (reviewed in Hatch, 1999), including genes that encode components of the 
outer-membrane complex (e.g., OmcA and B) and proteins involved in the condensation 
of the chromosome (e.g., HctA and B).  Microarray analyses have extended the number 
of genes expressed during this stage of development.  Belland et al, 2003b identified 26 
late genes including a number of genes previously characterized as late genes based on 
other molecular biological studies (e.g., omcAB, hctAB, ltuB, lcrH.1) and a number of 
new genes that encode proteins with speculative and unknown function.  Interestingly, 
expression of some late cycle genes may be directed towards the arming of EBs with 
proteins necessary during the early stages of the next infectious cycle (e.g., the TTSS 
protein LcrH.1), hence “late” genes may encode “early” proteins. 
 
 
1.3 PROMOTER ELEMENTS AND REGULATION 
 
 
1.3.1 PROMOTER ELEMENTS IN E. coli. 
 
The bacterial core RNA polymerase complex, consists of five subunits (ββ’α2ω), 
these subunits are sufficient for transcription elongation and termination but are not able 
to initiate transcription.  Transcription initiation from prokaryotic promoter requires 
another dissociable subunit (σ70 factor) (Burgess et al, 1969), which reversibly associates 
with the core RNA polymerase complex to form a holoenzyme RNAP.  (reviewed in 
Paget and Helmann, 2003). 
 
An RNAP-promoter complex capable of transcription initiation is formed through 
interactions that involve several regions of RNAP and that span 70–80 base pairs (bp) of 
promoter DNA (~−60 to +20) with respect to the transcription start site (TSS).  The 
majority of the sequence-specific interactions occur with the σ subunit.  In E. coli, 
sequence-specific interactions with σ70 occur at the −10 element (regions 2.3–2.4 in σ70), 
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the extended −10 element (σ70 region 3.0), the −35 element (σ70 region 4.2), and the 
discriminator element immediately downstream of the −10 hexamer (σ70 region 1.2), 
Figure  1-2; and (Haugen et al, 2008).  In addition, the C-terminal domain of α subunit 
can interact sequence-specifically with the UP element, located upstream of the −35 
hexamer (Gourse et al, 2000).  Other interactions also take place that are not sequence 
specific (Korzheva and Mustaev, 2001; Murakami et al, 2002; Vassylyev et al, 2007).  
(Reviewed in Ross and Gourse 2009). 
 
 
1.3.2 CHLAMYDIAL GENE REGULATION 
 
Control of the developmental cycle may have important translational and post-
translational components but the bulk of the experimental evidence suggests the primary 
mechanism involved is transcriptional regulation.  Genomic studies have shown that all 
species sequenced to date (Stephens et al, 1998; Read et al, 2000; Read et al, 2003) have 
a highly conserved multisubunit RNA polymerase that has many shared features 
compared to other eubacterial RNA polymerases (i.e. the core RNA polymerase consists 
of two α subunits and β and β’ subunits).  Three sigma factors (σ) that combine with the 
core polymerase to form the holoenzyme have also been found in all sequenced species.  
The chlamydial-specific sigma factors are the major sigma factor σ66 (Koehler et al, 
1990; Mathews and Stephens, 1999a; Douglas and Hatch, 2000) (orthologous to σ70 in E. 
coli) and the minor sigma factor σ28 (Mathews et al, 1999b; Yu and Tan, 2003; Shen et 
al, 2006) (orthologous to σ28 in E. coli) and the alternative sigma factor σ54 (Mathews and 
Timms, 2000) (orthologous to σ54 in E. coli).  Functional evidence has been demonstrated 
for several σ66 promoters and one σ28 promoter using mutational analysis and in vitro 
transcription assays (e.g. Ricci et al, 1993; Fahr et al, 1995; Douglas and Hatch, 1996; 
Tan et al, 1996; Tan et al, 1998; Ochiai et al, 1999; Schaumburg and Tan, 2003; Yu et al, 
2003; Yu et al, 2006). Chlamydial promoters share homology with each of the 
eubacterial consensus sequences with certain exceptions, including the presence of a cis-
acting, A/T spacer region in the majority of σ66 promoters analyzed (Schaumburg and 
Tan, 2000).  In addition, the stringency of consensus in chlamydial promoters appears to  
 
 
Figure  1-2  Consensus sequences for Eσ70 recognition elements and RNAP regions that 
interact with these elements. UP Element with α subunit C-terminal domains, −35 
hexamer with σ70 4.2, extended −10 element with σ70 3.0, −10 hexamer with σ70 2.3–2.4, 
and discriminator region element with σ70 1.2.  The TSS is indicated as (+1).  The most 
common spacing between recognition elements, in bp, with (range) is indicated.  Both the 
spacing of the −35 element with respect to the extended −10 element (14bp), and with 
respect to the −10 element (17bp) are shown.  Reprint by permission: Ross W, Gourse RL 
(2009) Analysis of RNA polymerase-promoter complex formation. Methods 47: 13-24. 
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be more relaxed than found in other eubacteria (Mathews and Sriprakash, 1994), allowing 
for changes in the consensus -10 and -35 regions of the promoters that interact with the 
major sigma factor.  This lack of stringency has hampered in silico efforts to identify 
promoters from complete genome sequences. 
 
Several transcriptional regulatory mechanisms have been found in Chlamydia 
including cis-acting DNA elements (Schaumburg et al, 2000), phosphorylation cascades 
(Koo and Stephens, 2003) and transcription factors (activators and repressors).  
Transcriptional regulators have been found that repress transcription.  HrcA has been 
shown to specifically bind a chlamydial CIRCE (Controlling Inverted Repeat for 
Chaperone Expression) element upstream of dnaK (Wilson and Tan, 2002), and a 
degenerate CIRCE element upstream of groELS (Wilson et al, 2005) and repress 
transcription of the dnaK and groELS genes. 
 
A distant relative of the E. coli fur gene has been identified in Chlamydia (termed 
dcrA) by complementation of an E. coli fur mutant and the ability to bind a 19 bp 
consensus operator sequence (or Fur box) found in promoters of iron-regulated genes 
(Wyllie and Raulston, 2001).  The repressor-operator binding kinetics of DcrA differ 
from the E. coli Fur protein suggesting that DcrA may have additional response cues than 
its E. coli counterpart or that the chlamydial operator sequence may differ from the 
consensus Fur box.  Other regulators include IHF (Zhong et al, 2001), TrpR (Akers and 
Tan, 2006), ArgR (Schaumburg and Tan, 2006) and ChxR (Koo et al, 2006). 
 
 
1.4  ALTERNATIVE GROWTH MODELS AND PERSISTENCE 
 
Many chlamydial diseases are associated with a long term or chronic infectious 
state.  In most cases it is difficult to establish whether chronic or recurrent infections arise 
through the inability of the host to resolve the infection or the occurrence of repeated 
infections with similar species or genotypes.  Despite the unresolved nature of the disease 
etiology, persistence models of chlamydial infection have been studied to provide insight 
into the nature of chronic disease (reviewed in Hogan et al, 2004).  Persistence is defined 
as a long-term association between Chlamydia and their host cell in which these 
organisms remain in a viable but culture-negative state.  The in vitro persistence systems 
often share altered chlamydial growth characteristics for example, many studies have 
described enlarged, and pleomorphic RBs that neither undergo binary fission, nor 
differentiate to EBs, but nevertheless continue to replicate their chromosomes.  These 
changes are generally reversible upon removal of the growth inhibitory factor (Hogan et 
al, 2004).  Persistent in vitro infections have been induced by penicillin treatment 
(Matsumoto et al, 1970), amino acid starvation (Coles et al, 1993), iron deficiency 
(Raulston, 1997), IFN-γ exposure (Beatty et al, 1993), monocyte infection (Koehler et al, 
1997), phage infection (Hsia et al, 2000), continuous culture (Kutlin et al, 2001).  This 
subject has been thoroughly reviewed in Hogan et al, 2004. 
 
IFN-γ mediated inhibition of intracellular chlamydial replication occurs by 
depletion of the essential amino acid tryptophan, via the induction of indoleamine-2,3-
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dioxygenase (IDO) (Beatty et al, 1994).  The effect of IFN-γ on chlamydial infection 
could be reversed by addition of tryptophan (Byrne et al, 1986).  Belland et al. have 
studied the induction of persistence with IFN-γ and the subsequent reactivation, using 
microarray analysis.  Persistent growth, characterized by large aberrant RBs, led to the 
up-regulation of genes involved in tryptophan utilization, DNA repair and recombination, 
phospholipid biosynthesis and translation.  Up-regulation of the repressible trp BA 
operon (Wood et al, 2003) confirms the previous observations that IFN-γ treatment 
reduces intracellular concentrations of tryptophan.  In addition, a number of early genes 
were up-regulated, particularly the euo gene (30-fold increase) which encodes a DNA-
binding protein that has been shown to bind to a late gene promoter region (i.e. omcAB 
(Zhang et al, 1998).  Down-regulation of genes involved in RB to EB differentiation (late 
genes such as hctAB and omcAB), proteolysis and peptide transport, and cell division 
were seen during persistent growth.  The transcriptional analyses were consistent with the 
biological properties associated with aberrant RBs in that cells were blocked in 
cytokinesis and the developmental cycle was arrested at a point preceding late gene 
expression.  Removal of IFN-γ and supplementation with added tryptophan led to a rapid 
reactivation from persistent growth.  During reactivation the expression differences 
rapidly returned to control levels, i.e. euo expression dropped 20-fold in 12 h.  This 
coordinated biological response appears to have evolved to allow the organism to rapidly 
respond to immunological pressure in a manner that allows for a period of resistance 
followed by rapid recovery after the waning of the host response. 
 
 
1.5 REGULATORY ncRNAs IN BACTERIAL PATHOGENS 
 
 
1.5.1 GENERAL 
 
Bacterial RNAs have long been known to encode the information for protein 
expression (mRNAs) and the structural components of the translational machinery 
(tRNAs and rRNAs).  Numerous studies have proved that there are other type(s) of RNAs 
with other functions.  For example, a number of abundant and frequently stable RNAs 
were identified by metabolic labeling and direct analysis by various fractionation 
procedures.  These included: 1) 4.5S RNA, part of the secretion machinery (Ribes et al, 
1990); 2) the catalytic part of the RNase P Ribozyme (M1RNA) (Robertson et al, 1972), 
that was found to be a ubiquitous endonuclease catalyzing the maturation of the 5' end of 
tRNA (reviewed in Kazantsev and Pace, 2006); 3) tmRNA, which serves an important 
role in translational quality control (Komine et al, 1994); 4) 6S RNA, which modulates 
RNA polymerase activity (Narayan et al, 1966; Barrick et al, 2005); and 5) Spot 42, an 
ncRNA that acts as an anti-sense regulator of the gal operon (Ikemura and Dahlberg, 
1973; Moller et al, 2002).  Not surprisingly, this sort of regulation is not confined to E. 
coli.  Phages, plasmids and transposons have long been recognized to use anti-sense RNA 
regulators involved in controlling copy number of plasmids, transposons, and the life 
cycle of bacteriophages (reviewed in Delihas, 1995; Wagner and Brantl, 1998; Wagner et 
al, 2002).  In eukaryotic cells, microRNAs and RNAi parallel in many ways bacterial 
ncRNA regulators; confirming that this level of regulation is widespread and is as central 
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to creating a working organism as are the more highly characterized protein regulators of 
transcription (Carrington and Ambros, 2003; McManus and Sharp, 2003). 
 
 
1.5.2 FUNCTIONAL ASPECTS 
 
Since the discovery of this new category of ncRNAs, several exhaustive searches 
have taken place.  This lead to the identification of approximately 80 ncRNAs in E. coli 
between 50 and 400 bases in size (1%–2% of the number of protein-coding genes) 
(Argaman et al, 2001; Gottesman et al, 2001; Rivas and Eddy, 2001; Wassarman et al, 
2001; Kawano et al, 2005).  Mechanistically, ncRNAs act through base-pairing 
interactions with other RNAs, thus inducing premature termination of message (Novick 
et al, 1989), mediating the destabilization of target mRNAs (Masse et al, 2003; Morita et 
al, 2005), promoting efficient translation of target mRNA (Majdalani et al, 1998), 
negatively regulating translation of target mRNA (Grieshaber et al, 2006) by mimicking 
the structure of other RNAs and DNAs (Willkomm and Hartmann, 2005), or as integral 
parts of protein-RNA complexes (Ribes et al, 1990) (reviewed in Storz et al, 2004; 
Gottesman, 2005 and Waters and Storz, 2009). 
 
Regulatory ncRNAs can be broadly divided into cis and trans-acting molecules.  
Cis-acting ncRNAs (also termed anti-sense RNAs) generally overlap the target gene and 
form extensive complementary stretches of double stranded RNA (dsRNA) that are 
degraded by RNase III (Vogel et al, 2004), or cause premature termination (attenuation) 
of transcription (Novick et al, 1989).  Trans-acting ncRNAs interact with non-
overlapping target mRNAs and the resulting RNA hybrids are generally degraded by 
RNase E (Masse et al, 2003), or the binding interaction interferes with recognition of the 
translational start portion of the mRNA (reviewed in Storz et al, 2004), or act as anti-anti-
sense where they remodel target RNA in favor of a translational permissive secondary 
structure (Majdalani et al, 1998).  Trans-acting ncRNA function is often difficult to 
predict since the anti-sense interaction generally occurs through a limited number of base 
pairs with the target mRNA, often using non-contiguous regions of the molecule folded 
into hairpin loops.  Many trans-acting ncRNAs have been shown to bind multiple target 
sequences; e.g. RyhB that binds to the mRNA of several iron metabolizing genes and 
possibly other targets as well (Masse et al, 2005). 
 
 
1.5.3 DETECTION METHODS 
 
Identification of bacterial ncRNAs has increased dramatically with the advances 
in genomic technology and the appreciation of the importance of these molecules in 
regulatory pathways.  Experimental approaches to identifying ncRNAs (reviewed in 
Huttenhofer and Vogel, 2006; Vogel and Sharma, 2005) have been diverse and include: i) 
direct metabolic labeling of abundant ncRNAs and detection by gel electrophoresis, ii) 
genetic screens for regulatory phenotypes that mapped to non-coding regions, iii) cloning 
of size fractionated RNAs, iv) bioinformatic identification of conserved intergenic 
regions, v) co-purification with RNA-binding proteins, and vi) microarray analysis of 
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intergenic regions.  Although each approach has strengths and weaknesses, a microarray 
analysis has become the method of choice for initial identification.  Traditionally, 
microarray design has been limited to regions coding for proteins, thereby omitting 
transcriptional measurements in intergenic regions (IGRs) where the majority of ncRNAs 
are encoded.  Recent studies with E. coli have utilized high-density microarrays that 
contain overlapping 25’mers oligonucleotide probes for all mRNAs, tRNAs, and rRNAs 
and IGRs (Selinger et al, 2000).  Although initially used to validate technical aspects of 
microarray profiling, a number of ncRNAs were confirmed using this procedure.  
Subsequent studies, specifically directed at ncRNA detection, have shown the approach 
to be particularly useful in analyzing ncRNA expression under different growth 
conditions (Wassarman et al, 2001; Tjaden et al, 2002).  An alternative approach has 
been used to analyze intergenic expression patterns in Staphylococcus aureus that 
involved PCR amplification of selected regions and arraying the dsDNAs on glass slides 
(Pichon and Felden, 2005). 
 
 
1.5.4 KNOWN EXAMPLES OF ncRNAs 
 
Recent studies have shown that, in addition to the plethora of protein repressors 
and activators, ncRNAs act as major regulators of adaptive responses in bacterial 
pathogens.  These ncRNAs control the global response of E. coli to oxidative stress 
(Altuvia et al, 1997), iron starvation (Masse et al, 2005), glucose starvation (Vanderpool 
and Gottesman, 2004), and the expression of outer membrane proteins and porins 
(Rasmussen et al, 2005; Udekwu et al, 2005).  Several pathogens utilize a cell-density 
based system (quorum sensing) to control the expression and secretion of virulence 
factors.  Non-coding RNAs were found to be the main effectors of quorum sensing 
systems in some organisms, e.g. in Vibrio cholerae, the expression of four redundant Qrr 
RNAs (quorum regulatory RNAs) is dependent on the quorum sensing protein 
(phosphorylated LuxO at low cell density) to block expression of the downstream 
effector, HapR (Lenz et al, 2004).  This leads to the up-regulation of a large number of 
virulence factors.  In Staphylococcus aureus, the expression of virulence factors is 
controlled by the expression of RNAIII that acts as the intracellular effector of the agr 
regulon (Novick and Jiang, 2003).  In Streptococcus pyogenes, the pel locus encodes a 
pathogenesis-related RNA that forms part of a signal transduction cascade that is 
dependent on the growth phase of the organism (Mangold et al, 2004).  The multifaceted 
effects of ncRNAs can be illustrated by the S.  aureus RNAIII (Novick et al, 2003) 
molecule, which controls the switch between the expression of surface proteins 
(colonization) and secreted toxins (pathogenicity).  The RNAIII molecule uses different 
structural domains to act in three different ways: 1) as a translational activator for hla 
(hemolysin δ) (Morfeldt et al, 1995); 2) as a translational inhibitor of spa mRNA; and 3) 
as a hemolysin mRNA (Novick et al, 2003).  RNAIII is also thought to regulate the 
expression of approximately 110 other genes, but it is not known if this is a direct effect 
on transcription or the result of post-transcriptional regulation of other transcription 
factors (Dunman et al, 2001).  Recently, Grieshaber et al, 2006 have shown that 
heterologous expression of a ncRNA from C. trachomatis can block translation of HctA 
(a chlamydial histone) in E. coli, thereby rescuing chlamydiae from the lethal effects of 
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HctA expression.  In addition, they demonstrated that the ncRNA (ihtA) was 
developmentally expressed in C. trachomatis at times in the cycle when HctA was not 
expressed. 
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CHAPTER 2.   MATERIALS AND METHODS 
 
 
2.1 MICROARRAY DESIGN AND CONSTRUCTION 
 
The custom microarray was designed in conjunction with the Affymetrix Design 
Team and purchased through support of the University of Tennessee Health Sciences 
Center and the UT Center of Excellence for Genomics and Bioinformatics.  The custom 
microarray is termed the “Multi-Pathogen Array, University of Tennessee number 1” or 
MPAUT-1, as it has representations of four chlamydial genomes of four different species.  
The species represented are C. trachomatis D (Stephens et al, 1998), C. pneumoniae AR-
39 (Read et al, 2000), C. muridarum (Read et al, 2000), and C. caviae (Read et al, 2003) 
and the complete genomic sequences are available on the TIGR website (www.tigr.org). 
 
The custom array format is a “CustomExpress Advantage 49-7875” that has 
approximately 253,000 addressable features (i.e. defined positions for 25’mer 
oligonucleotides termed “probes”).  Sequences of the complete ORFs for each species 
were submitted to the Affymetrix Design Team as FASTA files and probes were selected 
based on their evaluation process.  This process looks at all possible 25’mer probes and 
assigns probe scores based on a number of criteria including; thermodynamic properties, 
hybridization potential, synthesis steps, and cross-reactivity.  Cross-reactivity was 
addressed by a series of steps involving “hard” pruning (elimination of probes that cross-
react with abundant RNAs, i.e. rRNAs) and “soft” pruning (elimination of probes that 
cross-react with other sequences on the microarray and internal control sequences).  Each 
ORF is represented by a number of 25’mer oligonucleotides (mean value, 11 25’mers per 
gene) that are species-specific.  Each probe (termed Perfect Match or PM) has a 
corresponding mismatched probe (MM, altered at position 13, the middle of the 25’mer) 
to control for specificity.  The values reported for ORF analysis are therefore the mean 
value of the 11 measurements i.e. ∑𝑃𝑃𝑃𝑃 −𝑃𝑃𝑃𝑃 11⁄ . 
 
 
2.2 C. trachomatis GROWTH AND CELL CULTURE   
 
C. trachomatis serovar D (strain UW-3/Cx) was grown in HeLa 229 cells 
cultivated at 370 C with 5% CO2 in high glucose-containing DMEM (Cellgro, Mediatech) 
supplemented with 10% heat-inactivated FBS.  EBs were purified on density gradients of 
RenoCal-76 (Bracco Diagnostics, NJ) as previously described (Belland et al, 2003b).  
Monolayers were pre-treated with DEAE-Dextran (30 µg/ml) and infected at a 
multiplicity of infection (MOI) of 1.  PI timing began immediately following the addition 
of infectious EBs to the monolayers.  Growth in the presence of IFN-γ was done as 
described previously (Belland et al, 2003a).  5ng per ml IFNγ was used to induce 
persistence.  The amount of IFN-γ used was determined based on a titration experiment 
for the minimum amount of IFN-γ that induce persistence and allowed for reactivation.  
Carbenicillin-persistence was induced by adding 2 µg per ml antibiotic to the media at 
the time of infection.  Similar to the IFN-γ experiments, the amount of carbenicillin used 
was determined by a titration experiment that allowed for reactivation. 
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2.3 RNA PURIFICATION 
 
Total RNA was purified from infected HeLa 229 cultures (9 x 105 cells per well 
cultivated as monolayers in 6 well culture plates) at various times PI.  At the designated 
times PI, the culture media was discarded and cells lysed in 1 ml per well lysis buffer 
containing Proteinase K (0.167 µg/µl) (MasterPureTM, Epicentre) and total nucleic acid 
was isolated.  An aliquot of the lysate (300µl) was treated with RNase A (0.0167 µg/µl) 
and used to purify DNA.  The remainder of the lysate was treated with DNase I and used 
for total RNA preparation according to manufacturer’s instructions (MasterPure, 
Epicentre).  Purified DNA was quantified by qPCR and used for RNA normalization to 
calculated C. trachomatis genome numbers as previously described (Ouellette et al, 
2006).  RNA for microarray analysis was further purified from residual contaminating 
DNA by treating with DNase I (0.3U per 1 µg RNA) at 37oC for 1 hour (TurboDNAFree, 
Ambion).  RNA was then precipitated using sodium acetate (0.1 volume) and ethanol (3 
volumes) overnight at -20oC.  RNA was then pelleted by centrifugation, washed with 
80% ethanol and re-suspended in DPEC water (1µg/µl).  RNA (250 µg) was then 
enriched using the MICROBEnrichTM (Ambion) and MICROBExpressTM (Ambion) 
protocols, resulting in the removal of a significant portion of HeLa cell polyadenylated 
mRNA, 18S and 28S rRNAs in addition to bacterial 16S and 23S rRNA. 
 
RNA was reverse transcribed, hybridized, washed, stained, and scanned according 
to the Prokaryotic sample and array processing section in the GeneChip Expression 
Analysis Technical Manual (Affymetrix, CA).  In short, cDNA was generated from 
enriched RNA preparations using random primers (Invitrogen, CA) and Superscript RT II 
(Invitrogen, CA).  Following cDNA generation, RNA was removed by adding NaOH (1 
N) and incubating for 30 min at 65°C followed by neutralization in HCl (1 N).  cDNA 
was then purified using MinElute columns (Qiagen, CA).  cDNA was then fragmented 
using DNase I (Amersham, UK) using 0.6 U per 1μg of cDNA generated.  Fragmented 
cDNA products were then end-labeled using GeneChip DNA labeling Reagent 
(Affymetrix, CA) and Terminal Deoxynuceotidyl Transferase (Promega, WI).  
Fragmented and labeled cDNA were analyzed using 4-20% TBE gels (Invitrogen, CA) 
using a gel shift assay using NeutrAvidin (NeutrAvidin, Pierce).  The hybridization 
cocktail, consisting of labeled cDNA, control B2 oligo (Affymetrix, CA), herring sperm 
DNA (Promega, WI), and BSA (Invitrogen, CA) was then hybridized to MPAUT-1 
GeneChip and incubated for ca. 16 h in the Affymetrix Hybridization Oven 640 
(Affymetrix, CA) at 45°C rotating at 60 rpm.  Samples were then washed and stained on 
the Affymetrix Fluidics Station 450 (Affymetrix, CA) using Streptavidin (Pierce, IL), 
Anti-Streptavidin antibody (Vector Laboratories, CA), and R-Streptavidin Phycoerythrin 
(Molecular Probes, CA) and using fluidics protocol ProKGE-WS2_450 in GCOS 1.1 
(Affymetrix, CA).  After washing and staining, completed chips were scanned using the 
Genechip Scanner 3000 (Affymetrix, CA).  Data was scaled using GCOS 1.1 
(Affymetrix, CA) to a mean intensity of 1000 using the C. trachomatis ORF's as a scaling 
mask.  The pivot file for the sample was then saved in GCOS as a text tab delimited file 
and the data was imported into GeneSpring 7.2 (Agilent, CA) for data analysis. 
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2.4 QUANTITATIVE RT-PCR  
 
Primer/probe sets have been designed for C. trachomatis ompA using Primer 
Express software (Applied Biosystems, CA).  Standard curves were performed using 
purified chromosomal template DNA at concentrations ranging from 10 - 0.001 ng/ml 
(data not shown).  Assays were performed (Universal PCR System, Applied Biosystems) 
using DNA preparations of a portion of the sample for RNA purifications that were used 
for Northern Blotting.  Bacterial genome copy numbers were estimated by converting 
mean critical threshold (Ct) values to DNA concentrations (using Standard curves) and 
converting concentrations to copy numbers using the calculated molecular mass of the 
bacterial genome (7700 Sequence Detector, ABI Prism). 
 
 
2.5 RNA CIRCULARIZATION, AND 5’/3’ END SEQUENCING 
 
The procedure for RNA 5’/3’ end sequencing has been described previously 
(Vogel and Hess, 2001) and was used with some modifications.  A total of 8 µg of DNA-
free total RNA (DNased twice) prepared from 24 h PI cultures was treated with ten units 
tobacco acid pyrophosphatase (Epicentre, WI) for 30 min at 37°C to convert 5’ 
triphosphate groups of primary transcripts to 5’ monophosphates.  Following organic 
extraction, RNA was treated with 40 U of T4 RNA ligase (New England Biolabs, MA) 
overnight at 17°C.  RNA concentration during ligation was kept at 0.5 µg/50µl; this 
dilution allowed the reaction to proceed in the direction of intramolecular ligation 
(circularization) rather than intermolecular ligation (concatemerization).  Following 
organic extraction and ethanol precipitation, 1.5 µg of self-ligated RNA was converted to 
cDNA using gene specific reverse primes (Table  2-1) under 5’3’ SEQ application 
heading) and Superscript III (200 units) reverse transcription kit (Invitrogen, CA) in a 20 
µl reaction.  Incubation was carried out in 20-minute intervals at 42 °C, 50 °C, 55 °C, and 
60 °C.  After heat inactivation of the reverse transcriptase for 5 min at 85 °C, cDNA was 
treated with one unit of RNase H (New England Biolabs, MA) at 37 °C for 20 min.  A 
total of 1 µl of the reaction served as template in a subsequent standard 25 µl PCR 
reaction using TITANIUM Taq DNA Polymerase, TaqStart Antibody (1.1 μg/μl), 1x 
Advantage 2 SA PCR Buffer (Tris-HCl 1 mM (pH 8.5), KCl 5 mM, MgCl2 0.2 mM), and 
0.2 mM dNTP (Clontech, CA) and primer pairs designed to amplify products 
representing successful self-ligated ncRNA transcripts.  PCR products were separated by 
10% PAGE TBE gel electrophoresis (BIORAD, CA), and fragments of the expected size 
were excised, incubated overnight in 10mM Tris-HCl buffer then cloned into the pCR 
2.1-TOPO vector (Invitrogen, CA).  Positive colonies were picked, grown overnight in 
LB media with carbenicillin (50 µg/ml) and plasmid were prepare using MiniPlasmid 
Prep (Qiagen, CA).  Plasmids were sequenced using a standard M13 Forward primer. 
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Table  2-1  List of primers, organized according to application. 
 
Application/
Use Primer Name Sequence 
CTIG153 
Northern 
CTIG153_FWD_T7 
TAATACGACTCACTATAGGGAG
ATTCTCCGCGATGGCACCTTAA
T 
CTIG153_REV TGTGATAGCCTGAGCGTGTAGA
TG 
CTIG153band2_FWD_T7 TAATACGACTCACTATAGGTAG
CTCTTGCAGAGAAGCATCGTG 
CTIG153band2_REV 
CCGTCTCAAATGTCTACTGTCG
CT 
CTIG153 
5’3’ SEQ 
CTIG153 FWD 5'3' SEQ AGGTTCCCTTGAAAGACACGGT
CA 
CTIG153 REV 5'3'SEQ CCGTCTCAAATGTCTACTGTCG
CTGC 
CTIG153 
5’RACE 
CTIG153_GSP1 AGGTTCCCTTGAAAGACACGGT
CA 
CTIG153_GSP2 ACTACCATCCGGGAATGATTAG
ACGCTTCCGT 
CTIG241 
Northern 
CTIG241_FWD CCTTTGGAGTATATTTGAGGCG
G 
CTIG241_REV_T7 TAATACGACTCACTATAGGGGG
AGAACTCAGAGGG 
CTIG241 
5’3’ SEQ 
CTIG241 FWD 5'3'SEQ CCCTCTGAGTTCTCCCCCGAA 
CTIG241 REV 5'3'SEQ GGGTGCTGGTCACTAGCAAAAA
CTAGA 
CTIG241 
5’RACE 
CTIG241_GSP1 GGGAGAACTCAGAGGG 
CTIG241_GSP2 GGGTGCTGGTCACTA 
CTIG270 
Northern 
CTIG270_FWD CTACGTCATCTGTCAGAGAAAG
AGC 
CTIG270_REV_T7 
TAATACGACTCACTATAGGAGG
AATGGAATCGCAAATAGTGAG 
CT270 
Northern 
CT270_FWD ACACGCCTAGGGCTATCTCTTG
TT 
CT270_REV_T7 TAATACGACTCACTATAGGTCC
CTACAGGAGGTTTAGAGGCTT 
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Table 2-1 continued. 
 
Application/
Use Primer Name Sequence 
CTIG270 
Probe -219 
to -18 
CTIG270 FWD(-219) TTTAGCCGGAATATTCTGAAGA
AGTTGGTCTAAATG 
CTIG270 REVT7(-18) 
TAATACGACTCACTATAGGAGA
GTTACTTTTTTTGTGAAAGAGT
AAAAAGACGAGTTC 
CTIG270 
Probe -106 
to +67 
CTIG270_FWD(-106) GTCAAGCTTTGTCGACTAACTA
CGTCATCTG 
CTIG270_REVT7(+67) 
TAATACGACTCACTATAGGAGC
GGGAGAGGAAACTAATAATAA
AGA 
CTIG270 
Probe +83 
to +264 
CTIG270_FWD(+83) CTGCACACTCATCCCAAAGCAA
CA 
CTIG270 _REVT7(+264) TAATACGACTCACTATAGGGAG
AATAGCTTCTCGAGTGCTGCCT 
CTIG270 
Probe 
+275 to 
+494 
CTIG270_FWD(+275) AGCACACCGTCCTCCCATATAG 
CTIG270_REVT7(+494) TAATACGACTCACTATAGGACT
AAGGGATATTCTAGTGCAGGG 
CTIG270 
5’3’ SEQ 
CTIG270 FWD 5'3' SEQ CACTCATCCCAAAGCAACAGAC
CTCA 
CTIG270 REV 5'3'SEQ AGTGTGCAGCCTGGCATAAGGA
AA 
CTIG270 
5’RACE 
CTIG270_GSP1 GAGGAATGGAATCGCAAATAG
TGAG 
CTIG270_GSP2 TTGGGATGAGTGTGCAGCCTGG
CATAA 
ftsI-FLAG 
Cloning 
CT270_NoATG FWD AATCACCGTAGACAATTAACTC
TGATCGTTGTTG 
CT270 FWD+0.5FLAG 
GGACGACGATGACAAAAATCA
CCGTAGACAATTAACTC 
CT270 FWD FseI/FLAG ATTGGCCGGCCATGGACTACAA
GGACGACGATGACAAAAATCA 
CT270_REV+Stop/StuI 
ATTAGGCCTCTATTTGCGATTCC
ATTCCTCATATAGCAGCT 
LacP/O/S.D.+StuI_FWD ATTAGGCCTGCCGATTCATTAA
TGCAGCTGG 
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Table 2-1 continued. 
 
Application/
Use Primer Name Sequence 
ftsI-FLAG 
Cloning 
LacP/O/S.D.+FseI_REV AATCCGGCCGGTTTCCTGTGTG
AAATTGTTA 
CTIG270 
Cloning 
CTIG270_FWD/HindIII 
ATGAAAGCTTAGAAATGTTTTG
TTTGTGAGATGTAATTATGA 
CTIG270_REV/HindIII ATTAAAGCTTTACTAAGGGATA
TTCTAGTGCAGGG 
CTIG327 
Northern 
CTIG370_FWD_T7 TAATACGACTCACTATAGGACA
CCCGTCTCTAAGAAGTAGGCA 
CTIG370_REV_all gene GTAACAAGGTGTTGTGTAATCA
GAACT 
CTIG370_REV_PostTerm TTCTGGTCTACAGAGGGCTTT 
CTIG327 
5’3’ SEQ 
CTIG370 FWD SEQ 3'5' RT  TTAAGTACTGCTCGAACCCGTA
ACGC 
CTIG370 FWD 5'3' SEQ 
CGGAGTCCTTCGAATTACACCA
GGATCT 
CTIG370 REV SEQ3' 5' GTCAAAGCAAGCCTTCTGGTCT
ACAGAG 
CTIG327 
5’RACE 
CTIG370_GSP1 CCTCTGTAGACCAGAAGGCTTG
CTTTGACT 
CTIG370_GSP2 TCGGTCTCTATCCTTAAGTACTG
CTCGAACCCGT 
CTIG356 
Northern 
CTIG356_FWD_T7 TAATACGACTCACTATAGGTAA
CAGCACGTTCCACTACTCGCA 
CTIG356_REV GTTTATGTCTCAACTCAGCTAA
ACGC 
CTIG356 
5’3’ SEQ 
CTIG356 FWD SEQ 3'5' GGACCCAGCCGTCAGAACACTT
T 
CTIG356 REV SEQ 3'5' RT AGCTGCTTTGTTTGGGTGTTTGC
C 
CTIG360 
Northern 
CTIG360_FWD_T7 TAATACGACTCACTATAGGTAA
GAACAAGGACCCGGCGATAAC 
CTIG360_REV TCCTTTCATTTAGACTGGAGA 
CTIG360 
5’3’ SEQ 
CTIG360 FWD SEQ 3'5' CCGGCCTTTAAACCAACTACAG
ACATCC 
CTIG360 REV SEQ 3'5' CCGGATACCTTAGTGTCGATTC
GGTGAA 
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Table 2-1 continued. 
 
Application/
Use Primer Name Sequence 
CTIG360 
5’RACE 
CT359_GSP1 CTGCTATCCCACACATAGGACT
AC 
CT359_GSP2 AGAACAAGGACCCGGCGATAA
CCTTCACAA 
CTIG498 
Northern 
CTIG498 FWD  ACCTGGAACAGCAGAGTTGATT
GTGGCT 
CTIG498 REV_T7  
TAATACGACTCACTATAGGGGC
TTTCACCAGGCGATGGGAAGAA
G 
CTIG498 
5’3’ SEQ 
CTIG498 REV SEQ 3'5' RT CAGCATAATTTCGGAATCGAGC
G 
CTIG498 REV SEQ 3'5' CAGCATAATTTCGGAATCGAGC
GAAGTCT 
CTIG498 FWD SEQ 3'5' GGCTGTGAGTTCCCTGGATAAA
CAAGT 
CTIG504 
Northern 
CTIG504_FWD_T7 TAATACGACTCACTATAGGACA
AGAAGTTCTAGCACGCACGAC 
CTIG504_REV CCGAAGAATCTCAAGAGCAGCC
AA 
CTIG504 
5’3’ SEQ 
CTIG504 REV SEQ3'5' CTTCTTGTAAAGCTGTGGCGAG
GACT 
CTIG504 FWD SEQ3'5' RT 
AGTTCTAGCACGCACGACTGGA
AA 
CTIG643 
Northern 
CTIG643_FWD GCAAATTCTTGCTTTAGCAGGC
AGG 
CTIG643_REV_T7 TAATACGACTCACTATAGGTAA
GCGGGATCTTAGTCTCTCGCA 
CTIG643 
5’3’ SEQ 
CTIG643 FWD RT AAAGAGCTTATATGTGAAAGAC
TTTGTGT 
CTIG643 FWD SEQ 3'5' GCTCTTTTGAGAGCTTTCTTGGA
AAGCTTGA 
CTIG643 REV SEQ 3'5' CTCAAAAGAGCTTATATGTGAA
AGACTTTGTGTCATA 
CTIG643 FWD SEQ 3'5'-2 AGCGCGCTTCTTCCGCTCTT 
CTIG643 REV SEQ 3'5'-2 AGCCTTGTCAGGGACTTTAAAC
GGG 
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Table 2-1 continued. 
 
Application/
Use Primer Name Sequence 
CTIG675 
Northern 
CTIG675_FWD_T7 TAATACGACTCACTATAGGTTG
CAAGTTGGTATTCTAACGCC 
CTIG675_REV AAAGCCAAGAGAACCGGAGAT
ACG 
CTIG675 
5’3’ SEQ 
CTIG675 FWD SEQ 3'5' CCGTATCTCCGGTTCTCTTGGCT 
CTIG675 REV SEQ3'5' RT GGCTAACTCCAGTCCATCTTGA
CTTCC 
CTIG675 
5’RACE 
CTIG675_GSP1 TACGGCTAACTCCAGTCCATCT
TGACTTCC 
CTIG675_GSP2 CAAACACTAGAGTCAGAAGCTA
TTCCATGGCGTT 
CTIG675 
Cloning 
CTIG675 FWD CLONING ATTTTCATTAAGCCGAAAGTCA
TCAGTAGCTTCGA 
CTIG675 REV CLONING 
TACGAATGCGTTGCTCTACCAA
CTGA 
CTIG675 
Cloning 
under 
tetracycline 
promoter 
CCTIG675 FWD/Tc1 
GTGATAGAGATACTGAGCACAG
TTGCAAGTTGGTATTCTAACGC
C 
Add Tc1  
AGAGATTGACATCCCTATCAGT
GATAGAGATACTGAGCAC 
Add Tc2 
TCGAGTCCCTATCAGTGATAGA
GATTGACATCCCTATCAGTGAT 
Add Tc3 
CGTAGGTACCTCGAGTCCCTAT
CAGTGATAGAGATTGACA 
CTIG684 
Northern 
CTIG684_FWD GCAATACTCTCTCTGACTGTCT
AGC 
CTIG684_REV_T7 TAATACGACTCACTATAGGAGA
CAGCCTAGGGAAAGAGGATGT 
CTIG684 
5’3’ SEQ 
CTIG684 REV SEQ 3'5' RT 
AGACATCCTCTTTCCCTAGGCT
GTCT 
CTIG684 FWD SEQ 3'5' GGATGTCTCTCCCTAGACCCAA
GGAA 
CTIG684 
5’RACE 
CTIG684_GSP1 ACAGCCTAGGGAAAGAGGATG
TCT 
CTIG684_GSP2 AAGAGGATGTCTCTCCCTAGAC
CCAA 
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Table 2-1 continued. 
 
Application/
Use Primer Name Sequence 
Test SEQ 
Cloning 
CThctA FWD Infusion 
GATAGAGATACTAGGTAAAACT
GAAAAAAATAGTTTAAAACAA
CAACTAGAGGATATTTT 
Test SEQ Infusion REV_CAT GATTTTTTTCTCAGGCATGAAA
AAATATCCTCTAGTTGTTGT 
Test SEQ Infusion REV_tev 
ATTTTCACCGCCAGGCATGAAA
AAATATCCTCTAGTTGTTGT 
Test SEQ Infusion REV_ccdB 
AACCTTAAACTGAGGCATGAAA
AAATATCCTCTAGTTGTTGT 
CAT/ccdB 
CcdB_CAT FWD Infusion TGCGATGAGTGGCAGCAGTTTA
AGGTTTACACCTATAAAAGAGA 
ccdB REV Infusion 
TCCCCCGGGCTGCAGGAATTTT
ATATTCCCCAGAACATCAGGTT
AATGGCGTTT 
CAT FWD Tc1+StuI 
ATCAGTGATAGAGATACTAGGC
CTGAGAAAAAAATCACTGGATA
TACCACCGTTGATATA 
CAT FWD Tc2 
TCCCTATCAGTGATAGAGATTG
ACATCCCTATCAGTGATAGAGA
TACTAGGCCTGAGAAA 
CAT_Tc FWD Infusion 
TGGCAATTCCGACGTGACGTTC
CCTATCAGTGATAGAGATTGAC
ATCCCTATCAG 
CAT REV 
CTGCCACTCATCGCAGTACTGT
TGTAAT 
ccdB/CAT 
CAT FWD Infusion GAGAAAAAAATCACTGGATAT
ACCACCGTTG 
CAT Rev Infusion 
CTGCCACTCATCGCAGTACTGT
TGTAATTCATTAAGCATTCTGC
CG 
Tc ccdB FWD1 
CAGTGATAGAGATACTAGGCCT
CAGTTTAAGGTTTACACCTATA
AAAGAGAGAGCCGTTA 
Tc ccdB FWD2 
TGATAGAGATTGACATCCCTAT
CAGTGATAGAGATACTAGGCCT
CAGTTTAAGGTTTACA 
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Table 2-1 continued. 
 
Application/
Use Primer Name Sequence 
ccdB/CAT 
Tc ccdB FWD3 
TCCCTATCAGTGATAGAGATTGA
CATCCCTATCAGTGATAGAGAT
ACTAG 
Tc FWD Infusion 
CTGGCAATTCCGACGTTCCCTAT
CAGTGATAGAGATTGACATCCC
TATCAG 
ccdB REV Infusion CAT 
AGTGATTTTTTTCTCTATTCCCC
AGAACATCAGGTTAATGGCGTT
TTTGATGTCATTTTCGCGGT 
Origin 
Change 
SC101* FW Infusion ATCCGCCGCCCTAGACCTAGG 
SC101* REV Infusion 
GGGACTCTGGGGTTCGAGAGCT
C 
Sequencing 
pZA24 Fwd 
TGCGAAACGATCCTCATCCTGT
CTCT 
pZSC101&amp;15A REV 
SEQ 
AGGAGAGCGTTCACCGACAAA
CAACA 
pBAD 
Cloning 
TEV FWD INFUSION 
LIBRARY 
CCGCCCTAGACCTAGGACGTCT
GTGTGGAATTGTGAGCGGATA 
pBAD REV+RBS 
TATCCTTTCTCCTCTTTAATGAA
TTCTGTGTGAAATTGTTATCCG 
Tig144 
Cloning 
tig FWD Infusion 
AGAGGAGAAAGGATAATGCAA
GTTTCAGTTGAAACCACTCAAG
GC 
tig REV Infusion TGTTGATGAACGCATCAGAGTA
TCCAGCATGCCGTCAACGTCAG 
TEV for 
Tig144 
Cloning 
TEV REV CLONING  AAACCCGTACCCTAGCATAGGC
TTGGTTATGCCGGTACT 
TEV FWD CLONING2 
ATGCGTTCATCAACAAGTTTGT
ACAAAAAAGCAGGCTCGGGAG
AA 
TEV REV CLONING p15A GGAATATATCCCTAGCATAGGC
TTGGTTATGCCGGTACT 
TEV for 
pBAD 
Cloning 
TEV FWD CLONING for 
BAD 
AGAGGAGAAAGGATAATGCGT
TCATCAACAAGTTTG 
TEV REV CLONING  AAACCCGTACCCTAGCATAGGC
TTGGTTATGCCGGTACT 
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Table 2-1 continued. 
 
Application/
Use Primer Name Sequence 
TEV for 
pBAD 
Cloning 
TEV REV CLONING p15A GGAATATATCCCTAGCATAGGC
TTGGTTATGCCGGTACT 
Tctev/ccdB
_tev/CAT 
Cloning 
Lib Tc infusion/lib FWD 
CAGCTGGCAATTCCGACGTTCC
CTATCAGTGATAGAGATTGACA
T 
Lib Tc infusion/tev REV 
AAAATACAGATTTTCACCGCCA
GGCCTAGTATCTCTATCACTGAT 
Lib ccdB infusion/tev FWD 
GAAAATCTGTATTTTCAGAGTC
AGTTTAAGGTTTACACCTATAA
A 
Lib ccdB infusion/tev REV 
TCTGAAAATACAGATTTTCAGA
ACCTATTCCCCAGAACATCAGG
T 
Lib CAT infusion/tev FWD 
ATCTGTATTTTCAGAGTGGCGA
GAAAAAAATCACTGGATATACC
A 
Lib CAT infusion/lib REV CGGGCTGCAGGAATTTTACTGC
CACTCATCGCAGTACTGTTGTAA 
Tig144 
StuI 
Removal 
tig144 REV StuIREMOVE ACACGGCGGCCAAGGCCCTGAG
TGGTTTCAACTGAAACTTGCATT 
tig144 FWD StuIREMOVE ACCTATGAACTGTCGACTCGAG
CATAGCATTTTTATCCATAAGAT 
CcdB Add 
ATG 
ccdB FWD1 ADDATG TCAGGGCATGCAGTTTAAGGTT
TACACCTATAAAAGAGAGAGCC 
ccdB FWD2 ADDATG CCTGGCGGTGAAAATCTGTATTT
TCAGGGCATGCAGTTTAAGGTT 
ccdB FWD infusion ADDATG 
GATAGAGATACTAGGCCTGGCG
GTGAAAATCTGTATTTTCAGGG
C 
ccdB REV BmgBI infusion 
TATCTGACAGCAGACGTGCACT
GGCCAGGGGGATCA 
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2.6 ncRNA MAPPING USING 5’ RACE 
 
5’ Rapid amplification of cDNA ends (5’ RACE) is a technique used to determine 
the sequences at the beginning of RNA molecules; we used Super SMARTTMPCR cDNA 
Synthesis Kit (Clontech, CA) to determine the 5’ ends of RNA.  Briefly, RNA sample 
(1.5 µg) was mixed with gene specific primer(s)-1(GSP-1) (Table  2-1 under 5’RACE 
application) (84 pmoles total) and SmartOligo (84 pmoles), the mixture was heated to 
65°C for 2 minutes.  The reaction mixture was cooled to 42oC and mixed with reaction 
buffer (5x), DTT (2 mM, final concentration), dNTPs (2mM final concentration), RNase 
inhibitor (100 U, final concentration), and PowerScript Reverse Transcriptase (5 U, total) 
to generate the first-strand cDNA.  First-strand cDNA was then column purified using 
NucleoSpin columns (Clontech, CA).  cDNA was then amplified using Advantage II 
PCR kit (Clontech, CA) according to manufacturers instructions, we used SmartOligo 
primer and nested GSP-2 primers for amplification (Table  2-1 under 5’RACE 
application), the nested primer was designed downstream of GSP-1 to increase 
specificity.  The reaction was titrated by removing 20 µl aliquots from the reaction 
starting at cycle 15 and from every third cycle following to a maximum of 33 cycles.  
Reaction products were resolved on TBE-PAGE gels (10%), stained with ethidium 
bromide, visualized and excised from the gel for, cloning and sequencing (similar to  2.5 
above). 
 
 
2.7 NORTHERN BLOTTING 
 
Northern blotting was performed using 10% TBE-PAGE-Urea gels for RNA 
electrophoresis in 1 x TBE buffer.  RNA was transferred by electro-blotting, using plate 
electrodes, for 1 h at 50 V, using 1 x TBE buffer as transfer medium.  Zeta-probe GT 
nylon membranes (BIORAD, CA) were used for electro-blotting.  Single-stranded biotin-
labeled RNA Probes were prepared using a MAXIscript T7 Kit (Ambion, TX).  Target 
sequences were amplified by PCR using chlamydial DNA as a template and a minimal 
T7 promoter sequence was added 5' to the anti-sense strand (Table  2-1 under Northern 
application).  The resulting PCR fragment was fractionated on agarose gels, extracted, 
and used as a template for a larger scale PCR reaction.  PCR product was purified and 
was used as a DNA template for an in vitro transcription reaction using MAXIscript T7 
kit (Ambion, TX) and biotin-16-UTP (Roche, IN).  The reaction was carried out for 1 h at 
37°C, DNase treated for 15 min at 37°C, then the reaction was stopped by addition of 1 
µl 0.5M EDTA.  Buffer components and excess NTPs were removed by gel filtration 
using NucAway Spin Columns (Ambion, TX).  Hybridization was carried out in 
UltraHyb (Ambion, TX) medium overnight at 65°C.  Blots were washed using 
NorthernMax Low Stringency Buffer (Ambion, TX) at room temperature (2 x 5 min) and 
with NorthernMax High Stringency Buffer (Ambion, TX) at 65oC (2 x 60 min).  Northern 
blots were developed using alkaline phosphatase and streptavidin according to 
manufacturer’s protocols (BrightStarTM BioDetect, Ambion). 
 
 
 25 
2.8 GENERAL CLONING 
 
For cloning we used two different systems, the first was the regular 
restriction/ligation/transformation and the second was recombination/transformation; 
recombination was more versatile in its use, as it was not generally connected to a 
specific restriction site, it was fast and reliable. 
 
 
2.8.1 LIGATION 
 
For ligation we used Fast-Link™ DNA Ligation Kit (Epicentre, WI) where target 
plasmid was linearized by single or double digestion using NEB restriction enzymes 
(NEB, MA), plasmid was either dephosphorylated using FastAP™ Thermosensitive 
Alkaline Phosphatase (Fermentase, MD) followed by ligation, or the plasmid was blunt 
ended using T4 DNA Polymerase (End-It™ DNA End-Repair Kit, Epicentre) followed 
by dephosphorylation for blunt end ligation.  Insert was generally a PCR product, PCR 
products were gel purified, and either digested overnight by the appropriate restriction 
enzyme(s) for directional cloning or phosphorylated by T4 DNA Polynucleotide Kinase 
and ATP (End-It™ DNA End-Repair Kit, Epicentre) followed by ligation. 
 
The End-It™ DNA End-Repair Kit (Epicentre, WI) was used to convert DNA 
with 5'-protruding and/or 3'-protruding ends to 5'-phosphorylated blunt-end DNA for 
blunt-end ligation.  The conversion to blunt-end DNA was accomplished by exploiting 
the 5'→3' polymerase and the 3'→5' exonuclease activities of T4 DNA Polymerase, in 
addition, the enzyme mix also contained T4 DNA Polynucleotide Kinase and ATP carry 
out phosphorylation of the 5'-ends of PCR amplicons for subsequent ligation into a 
cloning vector.  The protocol was carried out as follows, DNA (up to 5 µg) was 
resuspended (or eluted) in 34 µl TE buffer (10 mM Tris-HCl pH 7.5, 1 mM EDTA), 5 µl 
aliquots of 10X Buffer (330 mM Tris-acetate pH 7.8, 660 mM K acetate, 100 mM Mg 
acetate,5 mM DTT), ATP (10 mM), and dNTPs (2.5 mM each) were added to the DNA, 
followed by 1 µl of T4 DNA Polymerase/T4 Polynucleotide Kinase Enzyme Mix.  The 
reaction mixture was kept at room temperature for 45 minutes followed by heat 
inactivation at 70°C for 10 min followed by column purification (MiniElute, Qiagen). 
 
Ligation was carried out by Fast-Link Ligation kit (Epicentre, WI), where 1.5 µl 
of 10X Fast-Link Ligation Buffer (330 mM Tris-acetate pH 7.8, 660 mM K acetate, 100 
mM Mg acetate,5 mM DTT), and 1.5 µl ATP (10 mM), were mixed with both vector and 
insert, the reaction volume was continued to 14 µl with water, then 1 µl Fast-Link DNA 
ligase (2U/µl) was added and the reaction kept at room temperature for 2 hour to over 
night.  In case the reaction was a blunt end ligation, the amount of ATP was modified to 
0.75 µl.  The reaction was heated at 70°C for 15 min then transformed into chemically 
competent or electrocompetent E. coli.  Calculation of insert and vector amounts used in 
ligation reaction were calculated as follows, the ratio of insert size to vector size was 
calculated and multiplied into the intended amount of vector to be used in nano grams 
then multiplied by 5, this equation calculated the amount in nano grams of insert used for 
ligation. 
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2.8.2 RECOMBINATION 
 
Recombination was carried out using In-Fusion™ Advantage PCR Cloning Kit 
(Clontech, CA), recombination was used to join multiple pieces of DNA that have 15 
bases of homology at their linear ends; recombination was typically used for fusing PCR 
products into vectors or joining different PCR products in one molecule with certain 
arrangement of DNA fragments dictated by the 15 base homology rule.  Recombination 
offered a cloning technique that did not require the use of restriction enzymes, ligase or 
phosphatase. 
 
The process first involved designing primers for insert amplification; the primers 
added 15 extra bases to each end of the amplicon, these extra bases were overlapping the 
ends of the linearized plasmid (Table  2-1 contains list of primers used for recombination 
under In Fusion application).  In case of blunt cutters (e.g. StuI, BmgBI, ScaI) and 5’ 
overhand cutters (AvrII, SalI, EcoRI) the 15 base overlap on the plasmid start at the 
cleaved nucleotide.  In case of 3’ overhand enzymes (AatII, SacI, KpnI), overlapping 
starts at the double stranded area of the plasmid ends, upstream of the single stranded 
staggered ends.  Insert was amplified using Phusion™ High-Fidelity DNA Polymerase 
(Finnzymes Oy, MS), followed by gel/column purification (MiniElute clean up kit, 
Qiagen).   
 
For recombining several PCR fragments together, all fragments were quantified 
and mixed to keep the molar ratio 1:1 as calculated by size ratio and concentration.  For 
cloning an insert into a vector, the vector was digested for 3 hours to overnight with the 
appropriate restriction enzyme(s); restriction time depended on the stability of the 
enzyme in the reaction (NEB literature) and the units of enzyme used.  Vector to insert 
molar ratio was 0.5, the amounts from each was calculated based on size ratios and 
concentrations.  All recombining DNA fragments were mixed and volume was completed 
to 7 µl with water, then 2 µl of 5X buffer were mixed followed by 1 µl In-Fusion 
enzyme.  The reaction mixture was then incubated at 37°C for 15 min followed by 15 
min at 50°C.  The reaction was stopped by adding 40 µl TE buffer then using 5 µl for 
transformation. 
 
 
2.9 PROTEIN GEL ELECTROPHORESIS AND WESTERN BLOTTING 
 
We used the NuPAGE® Bis-Tris Electrophoresis System (Invitrogen, CA).  It is a 
neutral pH, discontinuous SDS-PAGE, pre-cast polyacrylamide mini-gel system.  The 
neutral pH 7.0 environment during electrophoresis results in maximum stability of both 
proteins and gel matrix, providing sharp bands (Moos et al, 1988), samples were mixed 
with 2.5 µl of  4X NuPAGE® LDS Sample Buffer (106 mM Tris HCl, 141 mM Tris base, 
2% (Lithium dodecyl sulfate [LDS], 10% Glycerol, 0.51 mM EDTA, 0.22 mM SERVA® 
Blue G250, 0.175 mM Phenol Red, pH 8.5).  and 1 µl NuPAGE® Reducing Agent (500 
mM DTT), water was added to complete the volume to 10 µl.  Samples were heated at 
70°C for 10 min and then loaded on the gel.  Gels used were NuPAGE 4-12% Bis-Tris 
Gels, 1X running buffer was prepared by diluting 20X NuPAGE® MES SDS Running 
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Buffer (50 mM MES 50 mM Tris base 0.1% SDS 1 mM EDTA pH 7.3) and adding 
500µl of NuPAGE® Reducing Agent (500 mM DTT) per 200 ml of 1X NuPAGE® MES 
SDS Running Buffer.  The precast gel and running buffer were loaded into XCell 
SureLock.  Mini-Cell according to manufacturer’s instructions; gels loaded with 
preheated samples and protein Marker (BIORAD, CA) and were run at 200 volts for 1 
hour.  Gels were either stained or transferred to PVDF membranes for Western blotting.  
Staining was carried out as follows, NuPAGE® Gels were stained with SimplyBlue 
SafeStain (Invitrogen, CA), after electrophoresis, gels were placed in 100 ml of ultrapure 
water and microwaved on High (950 to 1100 watts) for 1 minute, gels were then put on 
an orbital shaker for 1 minute, the heating and shaking was repeated once more.  Water 
was drained and 20 mls SimplyBlue SafeStain was added and the gel was microwaved 
again for 45 seconds to 1 minute, followed by shaking for 5 min, gels were washed with 
100 ml of ultrapure water for 10 minutes on the shaker followed by 20 ml of 20% NaCl 
for 5 minutes where it was stored refrigerated. 
 
Transfer was carried out using XCell IITM transfer cassette was assembled 
according the manufacturer’s manual, transfer was carried out using 1X Transfer buffer, 
[20X NuPAGE® Transfer Buffer (25 mM Bicine, 25 mM Bis-Tris, 1 mM EDTA, pH 7.2) 
50 ml, NuPAGE® Antioxidant 1 ml, Methanol 100 ml, Deionized Water 849 m)].  
Electrotransfer was carried out at 30 volts for 1 hour.  Membranes were blocked over 
night using Blocking Buffer (1X TBS, 0.1% Tween-20, 5% w/v nonfat dry milk), 
membranes were washed 4X15min using TBS-T (1X TBS, 0.1% Tween-20), followed by 
incubation with the primary antibody diluted in the blocking buffer over night.  
Membranes were then washed 4X15 min using TBS-T, then incubated with the HRP-
secondary antibody diluted in blocking buffer for 3 hours, membranes were washed 4X15 
min using TBS-T and developed by ECL (Abcam, MA), the result was visualized using 
Kodak BioMax XAR Film (Fisher Scientific, PA). 
 
 
2.10 FUNCTIONAL ANALYSIS OF CTIG270 IN A SURROGATE SYSTEM 
 
To test the effect of expression of CTIG270 on ftsI, a system was constructed 
where both ftsI and CTIG270 were cloned in two compatible medium copy number 
plasmids and transformed into E. coli.  ftsI was fused in frame to a 5’ FLAG-tag sequence 
(N-DYKDDDDK-C) and cloned under the control of a lac promoter (from pCR2.1, 
Invitrogen) Figure  2-1. 
 
The FLAG-tag was added using PCR (Table  2-1 ftsI-FLAG Cloning and 
CTIG270 Cloning).  Cloning was carried out in a promoterless pSMART-LCAmp 
(Lucigen, WI).  PCR was used to add an FseI site to the 3’ end and 5’ end of the 
promoter and the FLAG-tagged ftsI respectively.  Both amplicons were digested over 
night with FseI followed by ligation.  The fusion product was then amplified by PCR and 
blunt end cloned into pSMART-LCAmp.  CTIG270 was cloned under the control of an 
arabinose responsive promoter (pBAD) in pRANGER-BTB vector (Lucigen, WI). E. coli 
transformed with both plasmids was induced with IPTG and/or arabinose.  E. coli was 
harvested and analyzed using Northern blotting for both mRNA and ncRNA.   
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Figure  2-1  Scheme for testing the function of possible cis acting ncRNAs.  The figure 
shows 2 plasmid system, one carries a FLAG-tagged target gene under pLAC promoter 
and the other carries the ncRNA under test controlled by pBAD promoter. 
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Northern blotting demonstrated transcription and stability of both RNAs.  FtsI protein 
was also checked using Western blotting. 
 
E. coli transformed with both plasmids was grown to an OD600 of 0.6.  The culture 
was split into three tubes.  One tube was induced with arabinose (0.2%), the second tube 
was induced with IPTG (1mM) and the third one was uninduced.  All three tubes were 
incubated at 37°C on a shaker for 2.5 hours.  A sample was collected from each test 
condition and cells were centrifuged.  Bacterial cells were used to prepare RNA 
(MasterPure, Epicentre) for Northern Blotting and protein for Western blotting.  
Following sample collection each culture tube received the second inducer.  The first tube 
was induced with IPTG (1mM), the second tube was induced with arabinose (0.2%) and 
the third tube was induced with both IPTG (1mM) and arabinose (0.2%).  The culture 
tubes were incubated at 37°C on a shaker for 2.5 hours and a second sample was 
collected from each tube as previously mentioned.  Culture tubes were incubated at 37°C 
on a shaker for 2.5 hours and the third sample was collected as previously mentioned.  
RNA and protein samples were resolved by gel electrophoreses and loading was 
normalized using OD600 measurements.  Protein samples were resolved on a NuPAGE 
Bis Tris gel and transferred onto a PVDF membrane according to manufactures 
instructions (Invitrogen, CA).  Western blotting was carried out using the ProteoQwest™ 
FLAG Chemiluminescent Western Blotting Kit (SIGMA-ALDRICH, MO).  RNA 
samples used for CTIG270 detection were resolved on a 10% Urea PAGE gels, while 
RNA samples for ftsI detection were resolved on a 1% formaldehyde agarose 
(NorthernMaxTM, Ambion).  RNA was then transferred to a Zeta probe GT Nylon 
membranes according to manufacturer’s instructions (BIORAD, CA).  Northern blotting 
was carried out using biotinylated RNA probes specific to CTIG270 and ftsI. 
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CHAPTER 3.   DISCOVERY AND VALIDATION PHASE 
 
 
3.1 CONSTRUCTION AND TESTING OF THE CHLAMYDIAL 
INTERGENIC MICROARRAY 
 
 
3.1.1 CONSTRUCTION OF THE CHLAMYDIAL INTERGENIC MICROARRAY 
 
Using intergenic microarrays for determining ncRNA expression represents an 
unbiased, hypothesis-neutral, and direct approach.  We have designed and constructed a 
GeneChip Custom Affymetrix microarray to determine the expression levels of ORFs 
and untranslated elements in IGRs of C. trachomatis D (strain UW-3/CX) based on the 
genomic sequence (Stephens et al, 1998). 
 
The IGRs of the C. trachomatis D and the C. pneumoniae AR-39 genomes that 
were 50 nucleotides or more were represented on the microarray.  IGRs were represented 
as 25 nucleotides probes tiled head to tail on both strands.  IGR probes present certain 
problems in the design process.  The defined nature of the target sequences (i.e. tandem 
25’mers) greatly restricted the selection process, and target probe acceptance values had 
to be lowered to a certain extent.  The initial design submission returned 82% of the tiled 
probes as acceptable.  To increase the flexibility of the algorithms selection process for 
the remaining 18% of the target regions were expanded by 5 nucleotides at the 5’ and 3’ 
ends (i.e. target sequence became 35 nucleotides) resulting in a coverage of 92% of the 
intergenic regions.  This process was repeated by extending the remaining 8% region by 
10 nucleotides in the 5’ and 3’ direction, resulting in 98% coverage of the intergenic 
region (6695 probes).  Certain probes could not be synthesized (145) due to secondary 
structure or synthesis step problems.  None of these were adjacent and therefore the 
transcriptional status of these regions can be conditionally estimated by comparison to 
flanking probes.  The need to lower acceptance values for probe design in the IGRs made 
the synthesis of MM probes questionable and, at the suggestion of the Affymetrix Design 
Team; these probes were not included on the microarray.  The expression results for the 
IGRs have therefore been interpreted in a contextual manner and require experimental 
controls. 
 
An example of the microarray results are shown in Figure  3-1 in which the 
fluorescence intensities of the microarray have been converted to a genomic “Array 
Layout” display for ORFs and IGRs (Belland et al, 2003b).  The region displayed in 
detail is the intergenic region containing CT269 (murE) and CT270 (ftsI) and a potential 
cis-acting ncRNA (CTIG270) that is expressed downstream of ftsI on the opposite strand.  
The display in Figure  3-1 shows each ORF as a single filled circle on the upper or lower 
strand depending on the orientation of the ORF (color represents the mean fluorescence 
intensity for the multiple ORF probes) while the intergenic region is shown as several 
double circles each representing a single 25 nucleotides probe on one of the two DNA 
strands (colors represent fluorescence intensity). 
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Figure  3-1  The MPAUT-1 microarray and a schematic display of experimental data.  
The figure shows the actual scanner-generated image of the array (the left hand side) and 
the array layout (right hand side): which is a computer generated image converting 
fluorescence intensities to colors of different shades (green being lowest expression and 
red being highest expression values).  The figure also shows a magnified segment of the 
chromosome detailing CT269, CT270 and a possible antisense RNA to CT270.  Each 
ORF is represented by a circle, the direction of the ORF dictates whether the circle is 
located on the upper line (upper strand) or on the lower line (lower strand).  The IGR is 
represented by a string of circles on both lines, each circle represent a single 25 mer 
probe. 
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3.1.2 TESTING THE MICROARRAY 
 
Intergenic microarrays pose a challenge because of probe quality, the limited 
space available within the target sequence for maneuvering, and getting a probe with 
good hybridization parameters.  Preliminary experiments were performed using C. 
trachomatis D chromosomal DNA.  Chromosomal DNA offered a linear representation 
of all sequences on the array at a 1:1 ratio.  We used labeled chromosomal DNA to check 
the intergenic microarray probe quality.  DNA from C. trachomatis D was fragmented 
via partial DNase I digestion (Amersham, UK) and Biotin end-labeled with terminal 
transferase (Invitrogen, CA).  The DNA array result summary is shown in Table  3-1. 
 
ORFs had a mean fluorescence intensity of 2008 arbitrary fluorescence units and 
a standard deviation of ±244.  This tight distribution is the consequence of each ORF 
being represented by 11-8 probe pairs (PM and MM) and the fluorescence represented 
the mean value according to the equation ∑𝑃𝑃𝑃𝑃 −𝑃𝑃𝑃𝑃 11⁄ .  On the other hand, probes 
representing IGRs had a mean fluorescence intensity of 2953 units and a standard 
deviation of ±1394.  The apparent wide range of the IGR results was because the 
fluorescence of each probe was reported as an individual event.  The DNA array analyses 
indicated that 399 out of 6695 (5.9%) probes in IGRs had a fluorescence value less than 
500.  The lower quality of these probes was taken into consideration when examining 
RNA microarray results. 
 
 
3.2 RNA PREPARATION 
 
RNA prepared from Chlamydia-infected cells is composed of a mixture of host 
RNAs (rRNA, mRNA, tRNA) and bacterial RNAs (rRNA, mRNA, tRNA) in which the 
former represents the vast majority.  To enrich for bacterial mRNA we tested procedures 
that selectively remove host mRNA and bacterial and host structural RNAs (rRNA and 
tRNA) but retained small sized RNA species.  Three enrichment procedures were carried 
out and compared using the MPAUT-1 intergenic microarray (summarized in Figure 
 3-2). 
 
The first condition (labeled 1 in Figure  3-2) was a process the involved the 
removal of host mRNA by treatment with a dC10T30 oligo-nucleotide linked to 
polystyrene-latex particles (OligoTexTM, Qiagen).  The second condition involved 
 
 
Table  3-1  C. trachomatis D-DNA microarray results summary. 
 
Parameter ORFs IGRs 
Mean fluorescence intensity 2008 2953 
Median fluorescence intensity 2004 2892 
Standard deviation 244 1394 
Highest value 2981 8015 
Lowest value 788 500 
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Figure  3-2  Enrichment procedures for chlamydial RNA for use with MPAUT-1. 
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the removal of host mRNA and structural RNAs (labeled 2 in Figure  3-2) using “capture” 
oligonucleotides coupled to magnetic beads that remove polyadenylated mRNA and 18S 
and 28S rRNAs (capture oligonucleotides are complementary to 18S and 28S sequences, 
MICROBEnrichTM, Ambion).  The third condition was an extension of the second 
procedure (labeled 3 In Figure  3-2) and involved further removal of bacterial 16S and 
23S rRNAs using capture oligonucleotides (complementary to 16S and 23S rRNA 
sequences of C. trachomatis, MICROBExpressTM, Ambion).   
 
The MPAUT-1 microarrays were used to compare the effect of these various 
enrichment methods on both sensitivity and specificity of the microarray.  Equivalent 
quantities of RNA were used for random-primed cDNA synthesis, fragmentation with 
DNase I, and labeling with biotin using T4 Terminal transferase (according to Expression 
and Analysis Technical Manual, Prokaryotic Probe Processing, Affymetrix). 
 
Comparison of different enrichment schemes indicated that all conditions showed 
acceptable levels of sensitivity.  Sensitivity was estimated based on the number of ORFs 
flagged as present in each experiment (814, 760 and 864 for the three treatment protocols 
respectively).  As shown in Figure  3-3, comparing the correlation coefficient of ORFs’ 
fluorescence values for each treatment against the MICROBExpressTM protocol showed 
high levels of reproducibility, (OligoTexTM to MICROBExpressTM had an R2 = 0.8228 
and MICROBEnrichTM to MICROBExpressTM had an R2 = 0.8764). 
 
The “scaling factor” calculation was used as an estimate of enrichment.  Scaling is 
a mathematical technique used by GeneChip Operating Software (GCOS) to minimize 
differences in overall signal intensities between two or more arrays.  This mathematical 
normalization allowed for a reliable detection of biologically relevant changes between 
different samples.  GCOS calculates the overall intensity of an array by averaging the 
intensity values of a preset reference probe matrix (in this case we set chlamydial ORFs 
as the reference matrix).  The average intensity of the array was then multiplied by the 
scaling factor to bring it to an arbitrary target intensity value (500).  Thus, scaling allows 
a number of experiments to become normalized to one target intensity, and direct 
comparisons between any two experiments can be carried out.  The scaling factor 
provided a measure of the brightness of the array.  This measure reflected the availability 
of bacterial mRNA in matched test samples.  By setting the reference probe matrix to 
chlamydial ORFs a high scaling factor can then be interpreted as a dim array, which 
might reflect lower abundance of chlamydial mRNA.  On the other hand, low scaling 
factors reflect a bright array; an indication of abundant chlamydial mRNA on the array.  
The calculated scaling factors for every enrichment scheme reflected the relative 
enrichment of bacterial mRNA in each sample as follows; for OligoTexTM and 
MICROBEnrichTM it was 25.8 and 36.5 respectively, while for MICROBExpressTM it 
was 2.5977.  For this reason we chose the MICROBExpressTM enrichment scheme for the 
following experiments. 
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Figure  3-3  Comparison of RNA purification protocols for use with the MPAUT-1 
microarray. 
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3.3 IDENTIFICATION OF C. trachomatis ncRNAs 
 
 
3.3.1 GUIDELINES FOR IDENTIFICATION OF C. trachomatis ncRNAs 
 
Potential ncRNAs were named using the IGR number corresponding to the 
downstream ORF using the CT numbers defined by Stephens et al, 1998 e.g. an ncRNA 
located upstream of CT241 is referred to as CTIG241.  C. trachomatis D RNA collected 
from 40 h post infection (PI) samples was processed and used to characterize the 
expression of ncRNAs.  Identification of potential ncRNAs was based on a number of 
guidelines including: i) sequential probes showing simultaneous expression (3 or more), 
ii) high levels of fluorescence from at least one of the IGR probes (>1000), iii) relatively 
high G+C ratio of the expressed region (elevated G+C ratios have been shown to predict 
biological function (Zhang et al, 2004)), iv) presence of rho-independent terminators at 
the end of the ncRNA, v) location with respect to flanking ORFs, and vi) genomic 
conservation with other chlamydial species.  An example of this type of analysis is shown 
in Figure  3-4 in which the expression of a potential ncRNA (CTIG241) is compared to 
expression of tRNA-Leu-2.  The IGRs and flanking ORFs are shown with corresponding 
expression levels and G+C ratio. 
 
 
3.3.2 RESULTS OF MICROARRAY SCREENING  
 
As shown in Table  3-2, House-keeping ncRNAs were used as a validation tool for 
microarray results.  We were able to detect all 37 tRNAs predicted in the genome of C. 
trachomatis D (including the tRNA-Leu-2 in Figure  3-4).  In addition, a number of highly 
conserved ncRNAs found in other bacterial genera were also detected.  These included: i) 
tmRNA (CTIG019), associated with the release of stalled ribosomes and the 
incorporation of a short peptide tag that targets the partial protein product for degradation 
(Withey and Friedman, 2003), ii) 4.5S RNA (CTIG255), which forms part of a 
ribonucleoprotein complex that plays a role in protein secretion (Poritz et al, 1990), iii) 
M1 RNA (CTIG399), which forms the catalytic subunit of RNase P, involved in 5’ tRNA 
processing (Kleineidam et al, 1993) and iv) and both 5S rRNAs (CTIG740 and CTIG750) 
which is involved in the ribosome assembly (reviewed in Gongadze et al, 2008). 
 
Microarray analysis showed that C. trachomatis D expressed 34 other intergenic 
sequences that met the guidelines for ncRNA identification.  These included ncRNAs that 
could be classified as cis-acting antisense molecules in that the expressed transcript 
overlapped the 3’ end of a transcript from an annotated gene in the opposite direction (as 
shown for CTIG270 ncRNA and ftsI gene in Figure  3-1, and for CTIG153 ncRNA and 
CT152 [lolD]).  Potential intergenic ncRNAs were also found that fit into the category of 
trans-acting molecules.  Table  3-2 summarizes the Northern blot results for all 34 
potential ncRNAs (14 potential ncRNAs were detected by Northern blotting).  An 
average G+C ratio of 0.41 was selected as a threshold ratio for ncRNAs.  This ratio was 
selected because this was the average G+C ratio for C. trachomatis D chromosome.  Out 
of the 14 transcripts detected by Northern blotting 3 ncRNAs had an average G+C 
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Figure  3-4  Guidelines for identification of the ncRNAs.  Identification involved the 
expression levels of a contiguous intergenic regions, G+C ratio, and position with respect 
to flanking ORFs.  Shown here is a comparison of the CTIG241 potential ncRNA and the 
tRNA-Leu.  Threshold levels for inclusion are shown as pink bars across the tiled 
intergenic regions. 
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Table  3-2  Results of the 40h PI microarray experiment showing all known ncRNAs 
(tRNA, tmRNA, 4.5SRNA, 5SRNA, M1RNA, and ihtA) in addition to potential 
ncRNAs. 
 
Name Approx. Size Class
1 A.F.U.2 Northern Rho Indpt3 
Average 
G+C Ratio 
37tRNAs 75-100 tRNA 25927 NA NA 0.51 
tmRNA 525 PI 24598 NA − 0.45 
4.5S RNA 100 PI 15917 Positive − 0.51 
5S rRNA 125 Ribosomal 32001 NA − 0.47 
ihtA 150 trans/3'UTR 9938 Positive √ 0.46 
M1 RNA 400 PI 20235 Positive − 0.43 
CTIG153 75 cis 884 Positive − 0.52 
CTIG241 75 trans 6073 Positive − 0.53 
CTIG270 100 cis 994 Positive − 0.36 
CTIG327 250 trans 1926 Positive √ 0.37 
CTIG356 225 trans/UTR 7238 Positive  0.44 CTIG360 200 trans/Riboswitch 4533 Positive √ 0.43 
CTIG498 100 trans/3'UTR 3976 Positive √ 0.46 
CTIG504 75 trans/3'UTR 3959 Positive √ 0.42 
CTIG582 200 trans 2135 Positive √ 0.39 
CTIG643 650 trans 7279 Positive √ 0.41 
CTIG684 100 trans 1420 Positive √ 0.47 
CTIG805 200 trans 5677 Positive − 0.37 
CTIG809 125 trans 748 Positive − 0.44 
CTIG857 225 trans 772 Positive − 0.45 
CTIG001 125 trans 1396 Negative − 0.35 
CTIG059 50 trans 1281 Negative − 0.57 
CTIG072 175 trans 2780 Negative − 0.39 
CTIG181 75 trans 4001 Negative − 0.36 
CTIG195 200 trans 1852 Negative − 0.4 
CTIG237 325 trans 6378 Negative − 0.4 
CTIG256 150 trans 1941 Negative − 0.38 
CTIG268 175 trans/5'UTR 5765 Negative − 0.43 
CTIG323 225 trans 4479 Negative − 0.41 
CTIG433 75 trans/5'UTR 2723 Negative − 0.44 
CTIG442 200 trans/3'UTR 2339 Negative − 0.4 
CTIG444 125 cis 3620 Negative − 0.37 
CTIG449 125 trans 4248 Negative √ 0.49 
CTIG592 150 trans 1335 Negative − 0.36 
CTIG660 125 trans/3'UTR 14347 Negative − 0.43 
CTIG663 250 trans 2784 Negative − 0.44 
CTIG775 175 trans 2877 Negative − 0.39 
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Table 3-2 continued 
 
Name Approx. Size Class
1 A.F.U.2 Northern Rho Indpt3 
Average 
G+C Ratio 
CTIG813 225 trans 1364 Negative − 0.34 
CTIG864 125 trans 19393 Negative − 0.41 
 
Approximate sizes are based on the array, the potential functional class, the average 
fluorescence of the probes representing the ncRNA, presence of Rho independent 
terminator, and the average G+C ratio across the region in question. 
1 Class of ncRNA refers to its presumed mode of action.  PI is protein interaction.   
2 A.F.U.  Average Fluorescence Units. 
3 Rho indpt is Rho Independent terminator as analyzed by www.softberry.com. 
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ratio bellow 0.41. All other tested ncRNAs and house-keeping ncRNAs had an average 
G+C ratio between 0.43 and 0.53. 
 
Interestingly, 8 of these 14 ncRNAs had a potential rho independent terminator.  
ncRNAs that were not detected by Northern blotting generally had lower G+C ratio (11 
out of 20 were bellow 0.41), and 1 had a potential rho independent terminator.  
Collectively these results pointed to the potential expression of new, previously 
uncharacterized, RNA molecules during the normal developmental cycle of C. 
trachomatis D. 
 
 
3.3.3 VALIDATION OF ncRNA EXPRESSION 
 
RNA samples were DNAsed (TurboDNAse, Ambion) and resolved on 10% 
UREA PAGE gels (Criterion, BioRad), transferred onto nylon membranes (GT-Zeta-
Prob GT, BioRad), and probed with biotin-labeled single stranded RNA probes.  The 
probes were prepared by adding a T7 minimal promoter sequence to PCR amplified IGRs 
(Northern Blotting, section  2.7 above).  The microarray was used as guide to determine 
the orientation of the potential ncRNA (thus decide which strand to probe) and to narrow 
the target area, thus preventing interfering signals from nearby genes and/or tRNAs.  T7 
PCR products were then subjected to an in vitro transcription reaction containing 16-
UTP-BIOTIN (Roche Applied Science, IN).  The product was then DNAsed and stored at 
-80°C.  By selecting the correct primer for the T7 promoter and by decreasing the size of 
the PCR to a minimal size (150-200 bases), we were able to probe every potential 
ncRNA.  The Blots were then visualized by streptavidin bound alkaline phosphates and 
treated with the substrate, CDP-Star according to manufacturer’s instructions (BrightStar, 
Ambion).  Table  2-1 shows a list of primers used for probe preparation and Northern 
blotting. 
 
A subset of the potential ncRNAs that were verified by Northern blotting (Figure 
 3-5) included CTIG153, CTIG241, CTIG270, CTIG327, CTIG356, CTIG360, CTIG498, 
CTIG504, CTIG643, and CTIG684.  Figure  3-5 also showed the results of some known 
ncRNAs including tRNA leu, 4.5S RNA, M1 RNA, plasmid antisense transcripts (Fahr et 
al, 1992), and ihtA (Grieshaber et al, 2006).  ihtA has been shown to translationally-
silence expression of the chlamydial histone HctA in a heterologous E. coli co-expression 
system.  A schematic of the chromosomal arrangement of the locus for each ncRNA is 
shown in Figure  3-6. 
 
CTIG153 had two products ranging in size from 120 to 170 nucleotides (Figure 
 3-5).  The chromosomal locus in Figure  3-6 showed that CTIG153 is located on the lower 
strand running towards CT152.  Upon further inspection, a rho independent terminator 
was detected 14 bases upstream from the CT152 stop codon creating a possible overlap of 
60 nucleotides between the ncRNA and CT152 (14 bases upstream of the terminator plus 
46 nucleotides that form the terminator stem loop).  This architecture is strongly 
suggestive of an antisense mode of action.  Moreover, the fact that the Northern blot 
showed two bands suggest that CTIG153 is processed in the course of interaction with 
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Figure  3-5  Northern blotting of potential ncRNAs from C. trachomatis at 40 h PI.  
House-keeping small RNAs (RNase P, 4.5S RNA, and tRNA-Leu-2) and several novel 
(CTIG153, 241, 270, 327, 356, 360, 498, 504, 643, and 684) and previously described 
IhtA (Grieshaber et al, 2006) and plasmid antisense transcripts (Fahr et al, 1992) RNAs 
are shown.  Chlamydial ncRNAs were probed with strand-specific, biotin-labeled probes 
using equivalent amounts of non-enriched RNAs.   
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Figure  3-6  A schematic of the chromosomal locus for each ncRNA shown with the two 
flanking genes.  Black arrowheads represent ncRNA and gray arrowheads represent 
tRNAs. 
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CT152.  The small band might be a partially processed RNA that is missing its 3’ end.  In 
order to prove this hypothesis another set of probes were designed.  One overlapped the 
5’ end of CTIG153 and the other overlapped its 3’ end.  Northern blotting showed that 
only the 5’ probe was able to identify both bands while the 3’ probe identified the large 
product only (data not shown). 
 
CTIG241 is located upstream of CT241.  Generally ncRNAs located upstream of 
genes on the same strand might be 5’UTR for those genes.  CTIG241 is located about 50 
nucleotides downstream of CT240 and 250 nucleotides upstream of CT241.  Although no 
obvious rho independent terminator was located in the vicinity of the ncRNA; a classical 
stem loop ending in a group of Us was located at the 3’ end of the ncRNA.  This potential 
terminator was not reported by the software (www.softberry.com) because it was 
destabilized by two bulges.  The software might have assigned this terminator an inferior 
score.  Analysis of the G+C ratio in this locus shows an unusual bias towards a high the 
G+C ratio in the ncRNA location (Figure  3-4).  CTIG241 does not overlap with flanking 
genes which makes it a potential trans-acting ncRNA. 
 
CTIG270 deviated from the guidelines of selection of ncRNAs in several aspects.  
It had a low G+C ratio (0.36), and had no terminator structure within the IGR or in the 
downstream gene (Table  3-1).  The sequence directly upstream of CTIG270 contained 
several repeats suggesting a protein-DNA binding site(s).  The signal detected on the 
Northern blot for CTIG270 was considered the weakest in all the examined ncRNAs.  
The chromosomal arrangement showed that CTIG270 ran on the upper strand and 
overlapped the 3’ end of CT270 (ftsI).  The architecture suggests an anti sense 
mechanism of action that affects the stability of ftsI.  On the contrary to CTIG153, a 
single major product was detected for CTIG270.  This was possibly due to complete 
degradation of the ncRNA when it interacts with its target gene.  Comparing the 
chromosomal locus in both C. trachomatis and C. muridarum revealed that the locus in 
C. muridarum contains an annotated ORF in place of CTIG270.  The annotated ORF was 
located on the upper strand opposite to the flanking genes.  Its first ATG overlapped 
murE coding sequence by 15 nucleotides (named murG in C. muridarum) and ends 7 
nucleotides before the ftsI stop codon.  The presence of this ORF led us to investigate if 
CTIG270 as identified in C. trachomatis represented a pseudogene.  In order to address 
this question, we synthesized a series of ~200 nucleotide probes spaced over  the IGR 
from the start of murE to ~500 nucleotides inside ftsI, (Table  2-1 primers listed under 
Probe -219 to -18, Probe -106 to +67, Probe +83 to +264, and Probe +275 to +494, 
numbering starts at CTIG270 TSS as +1) Northern blot analyses indicated that CTIG270 
was located 100-200 nucleotides upstream of ftsI stop codon, and about 100-200 
nucleotides downstream of murE start codon.  Probe -219 to -18 covered the area where 
the possible pseudogene would be located.  This probe failed to detect CTIG270.   
 
CTIG327 is located 200 nucleotides downstream of CT326.2 and 250 nucleotides 
upstream of CT327.  All three genes were located on the lower strand and in the same 
orientation.   There was a rho independent terminator located at the end of CTIG327.  
Upon examining the sequence within this intergenic region, a possible unannotated ORF 
of 204 nt was found overlapping CTIG327.  The unannotated ORF ended 42 nt 
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downstream of the rho independent terminator.  We investigated whether the product 
detected on the Northern blot represented CTIG327 or represented the unannotated ORF.  
Two probes were designed.  One overlapped the 5’ end of the message and the other 
overlaps the region downstream of the terminator.  Northern blotting result showed that 
the product could only be detected when using the probe overlapping the 5’ end.  This 
result showed that the product belongs to the ncRNA not the unannotated ORF (data not 
shown). 
 
CTIG356 and CTIG360; both had similar chromosomal arrangements. Their 
arrangements suggested that they might be 5’ UTRs for there upstream genes (CT355 and 
CT359 respectively). Table  3-2 denoted CTIG360 as a potential riboswitch.  
Riboswitches are RNA elements that undergo a shift in structure in response to binding of 
a small molecule.  Such structural shifts affect stability and or translatability of the 
message.  These elements are encoded within the transcript they regulate.  They act in cis 
to control expression of the coding sequence within that transcript.  Riboswitch RNAs 
control a broad range of genes in bacterial species, including those involved in 
metabolism, uptake of amino acids, cofactors, nucleotides, and metal ions (reviewed in 
Henkin, 2008).  CTIG360 was located directly upstream of CT359, which is a bioY gene.  
Orthologue of bioY in Rhodobacter capsulatus was able to confer biotin uptake 
phenotype to a mutant E. coli strain that was deficient in biotin uptake (Hebbeln et al, 
2007).  Latter results will add more to this discussion. 
 
CTIG498 and CTIG504 overlapped the 3’UTR of CT497 and CT504 
respectively.  Both genes were reminiscent of ihtA chromosomal arrangement.  Both 
ended in a rho independent terminator.  Moreover, CTIG504 and ihtA have a tRNA 
directly downstream of the rho independent terminator. 
 
CTIG643 and CTIG684 were located in the middle of the IGR, on the upper 
strand and in the same direction as the downstream genes.  Both ended in a rho 
independent terminator.  CTIG643 showed two products on the Northern blot.  Two 
probes overlapping the sequences flanking the terminator were prepared.  Northern blot 
showed that the small product represented the sequence upstream of the terminator, and 
the larger product contained both sequences upstream and downstream of the terminator.  
CTIG684 On the other hand, was represented by several small products around 50-70 
nucleotides.  RNA probes upstream and downstream of the terminator showed that all 
products represented sequences upstream of the rho independent terminator. 
 
 
3.4 DISCUSSION 
 
 
3.4.1 USE OF THE TILING MICROARRAY PLATFORM 
 
The primary hurdle facing ncRNA discovery is the absence of a clear signature 
element(s) in the primary genome sequences.  Preset assumptions of possible signature 
sequences have been implemented to find candidate ncRNAs.  The majority of confirmed 
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ncRNAs were identified primarily by comparative sequence analysis to identify 
conserved elements in IGRs.  Additional sequence signatures including intergenic 
promoter elements, sequences predicted to form stable RNA secondary structures, and 
intergenic rho-independent terminator elements have also been used for the screening of 
candidate ncRNAs (Argaman et al, 2001; Rivas and Eddy, 2001a; Rivas et al, 2001b; 
Livny et al, 2005). 
 
In such a new field there still not enough data that conclusively mandate using the 
aforementioned signature elements as the main method of screening for ncRNAs.  In 
addition, the less biased shotgun cloning approach has identified highly expressed 
ncRNA candidates in E. coli that were missed by comparative analyses (Vogel et al, 
2003). 
 
We have used a different unbiased strategy to identify ncRNAs in C. trachomatis.  
In this strategy we used a custom tiled Affymetrix microarray combined with an 
experimental protocol and analysis scheme optimized for ncRNA detection.  We first 
scored the quality of each individual intergenic probe by hybridizing chromosomal DNA 
to the microarray.  We then tested RNA samples, and analyzed each IGR for 
simultaneous high levels of florescence of 3 or more consecutive probes.  Each potential 
IGR was further inspected for rho independent terminators, localized high G+C ratio, 
conservation among various sequenced chlamydial species, and finally analyzed by 
Northern blotting using strand specific RNA probes. 
 
The E. coli high-density microarrays were used to identify ncRNAs.  Both total 
RNA and RNAs isolated by co-immunoprecipitation with the RNA binding protein, Hfq 
were used for screening (Tjaden et al, 2002; Zhang et al, 2003; Hu et al, 2006).  High-
density microarrays, combined with comparative genome analysis, had led to the 
identification of mostly growth phase dependent ncRNAs in E. coli and Staphylococcus 
aureus and of ncRNAs whose expression is under the control of sporulation in Bacillus 
subtilis (Wassarman et al, 2001; Pichon and Felden, 2005; Silvaggi et al, 2006).  
Although DNA microarrays are a valuable tool for both identification and transcription 
profiling of ncRNAs it, like all other approaches, bears some caveats.  One of the most 
challenging aspects of this technique is the preparation and labeling of RNA samples.  
The small size and structure of ncRNAs make these transcripts poor substrates for 
amplification and labeling.  In addition, shorter ncRNAs (< 50 nucleotides) might be 
harder to detect, especially if the probes were arranged head to tail with no overlap.  
Therefore, short ncRNAs and ncRNAs that are highly structured and/or modified were 
likely to be missed.  This phenomenon was observed in case of CTIG153.  Its average 
fluorescence on the array was 884 (Table  3-2) while the Northern blotting showed high 
level of transcription (exposure time for developing the Northern blot was seconds).  A 
novel detection method employing antibodies specific for RNA–DNA hybrids 
circumvented the problem of labeling and was shown to improve sensitivity (Zhang et al, 
2003; Hu et al, 2006), and probably would be worth checking for future microarray 
experiments, this method was also recommended by S. Gottesman (Personal 
communication, 2005). 
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3.4.2 PROBE QUALITY AND RESULT INTERPRETATION 
 
DNA microarray result uncovered considerable variations in probe sensitivity.  
This observation was confounded by the absence of mismatch probes.  It was 
recommended by the Affymetrix design team to disregard inclusion of the MM probes.  It 
was reasoned that since IGR probes were tested individually, the statistical package that 
calculates the average fluorescence for each gene would not be fully functional and there 
was no need to include MM probes.  Moreover, elimination of MM probes increased the 
available features on the microarray and increased the allowed synthesis steps by 4 
rounds.  Comparing the MPAUT-1 with the high density microarray for E. coli (Tjaden et 
al, 2002), we noticed the difference in probe selection protocol.  MPAUT-1 probes were 
arranged head to tail with no intentional overlaps.  On the other hand, the high density 
microarray probes were selected every 4 nucleotides.  Whether this denser probe 
selection scheme offered more validity for the results is unknown, but the high density 
version offered a worthwhile alternative.  Tjaden et al, 2002 preformed a similar set of 
quality control tests for the IGR probes.  Initial analysis of the data across all experiments 
(total of 26 microarrays) showed a range of hybridization affinities for different probes.  
2671 probes were eliminated from the analysis for which there was evidence of 
significant cross-hybridization or other non-specific hybridization.  Bad probes were also 
determined by hybridizing E. coli genomic DNA labeled directly with terminal 
transferase to the microarray and eliminating the probes that failed to meet expected 
values.   
 
Zhang et al, 2003 developed a rating system for analyzing microarray data.  IGRs 
were rated 5 if the average probe florescence was ≥10,000, an average fluorescence 
intensity of ≥5000 was rated 4, an average probe florescence of ≥1000 was rated 3, and 
finally an average probe florescence of ≥200 was rated 2.  Candidate IGRs were analyzed 
by Northern blotting. 
 
The field of genome sequencing and genome wide transcriptome sequencing is 
getting faster, more efficient, and more cost effective by time.  Lately a new technology 
has emerged where whole transcriptomes were sequenced in a bead based emulsion PCR.  
The cDNA was ligated to adapters, clonally selected on the beads and amplified via 
emulsion PCR.  Several samples could be pooled (up to 20 samples) using bar coded 
adapters and all the beads were deposited on slides and sequenced in parallel by repeated 
rounds of hybridization and ligation of fluorescently labeled di-base probes followed by 
cleavage and detection (The SOLiD™ 3 System, Applied Biosystems).  This system had 
the advantage of generating actual sequences as readouts rather than fluorescence.  Based 
on the number of times a sequence appeared the relative abundance of the message was 
calculated.  The SOLiD technology, being non sequence dependent, also had the 
advantage of getting sequences of previously un-identified transcripts.  This sequencing 
based detection offered a solution to a problem that was seldom addressed using other 
techniques.  It offered an easier way to detect antisense ncRNA that are totally buried 
within annotated genes.  Future experiments are being planned involves using this 
platform. 
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3.4.3 POTENTIAL ncRNAs IN C. trachomatis D 
 
Comparative genomics of ncRNAs in bacterial genomes found that on average, 
ncRNAs are found in approximately 30% of IGRs of each genome sequence.  Of these, 
25.7% are conserved among three or more organisms.  Approximately 60% of the 
conserved ncRNAs are not located in orthologous IGRs, implying that ncRNAs may be 
shuffled in genomes (Luban and Kihara, 2007).  The potential ncRNAs in Chlamydia 
were located 5’and 3’ to annotated genes.  Since no functions have been assigned to any 
of the ncRNAs (except ihtA), there remains the possibility that they represent processed 
5’ and 3’ RNAs.  Some established ncRNAs in other bacteria were located in the vicinity 
of flanking genes.  6S RNA, a major regulator of E. coli σ70, was produced as a part of a 
longer message (Trotochaud and Wassarman, 2004; Wassarman, 2007).  Another 
example is RNAIII, a bifunctional molecule that encodes the δ-hemolysin protein in its 5′ 
end while it also acts as an ncRNA (Janzon et al, 1989).  Examining the chlamydial 
chromosome revealed several indications that several functional genetic elements are 
packed within a limited space.  For example, Chlamydia has 6 tRNAs (out of 37) that 
were located just 24 to 37 nucleotides upstream of genes on the same strand.  In order for 
the transcripts of these genes to be independent, a distance of at least 45 nt was required 
between them and the closest tRNA (35 nucleotides promoter and shine Dalgarno 
sequence).  In addition 8 pairs of tRNAs belonged to bicistronic operons.  Moreover, the 
only known chromosomally encoded ncRNA in Chlamydia (ihtA) was located 16 
nucleotides downstream of yscC and directly upstream of a tRNA.  These observations 
indicated that Chlamydia has limited space to fit several genetic elements within a 
confined spac. 
 
 
3.4.4 CTIG270 AND ftsI 
 
In E. coli, ftsI was involved in the biosynthesis and degradation of the murein 
sacculus and peptidoglycan.  It was specifically localized to the division septum.  
Invagination of the cytoplasmic membrane was accompanied by the synthesis of 
peptidoglycan at the leading edge of the invagination.  This septal specific peptidoglycan 
biosynthesis occurred in two stages (Woldringh et al, 1987; Wientjes and Nanninga, 
1989; Nanninga, 1991).  An early stage that is penicillin insensitive and a later stage that 
is sensitive to penicillin and requires PBP3, the product of the ftsI gene (Botta and Park, 
1981; Spratt, 1977). 
 
Identification of CTIG270 as a potential antisense regulator of ftsI added more 
questions to an already puzzling situation ( 1.2.6 above).  dicF an ncRNA inhibited the 
translation of ftsZ (Faubladier and Bouche, 1994; Tetart and Bouch, 1992).  It was 
established as the smallest ncRNA that had an assigned function (53 nucleotides).  
Probably Chlamydia which lacks ftsZ was using another ncRNA to control another key 
enzyme in peptidoglycan synthesis.  To our knowledge there was no precedence for an 
antisense RNA that regulates a penicillin binding protein.  Whether CTIG270 represents a 
key molecule in regulating cell division remains to be determined.  Another question was 
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the involvement of other PBPs encoded by the chlamydial genome in this regulatory 
circuit. 
 
Sequence inspection revealed more information about this ncRNA.  CTIG270 had 
a 15 nucleotides complementarity to a sequence 200 nucleotides downstream of ftsI start 
codon.  Similar finding was observed in C. muridarum CTIG270/ftsI orthologues.  The 
result of binding of CTIG270 to ftsI could either be degradation or stabilization of ftsI.  In 
E. coli gadY ncRNA was shown to overlap the 3' end of gadX gene.  This overlap region 
was found to be necessary for the gadY-dependent accumulation of gadX mRNA.  It was 
suggested that during the stationary phase gadY base paired with the 3'-untranslated 
region of gadX mRNA and conferred increased stability.  This allowed gadX mRNA to 
accumulate and increased the expression of downstream acid resistance genes (Opdyke et 
al, 2004; Tramonti et al, 2008). 
 
 
3.4.5 CTIG360 AND bioY 
 
Biotin represents an important metabolite for both eukaryotes and prokaryotes.  
Biotin is a water-soluble vitamin that participates as a cofactor in gluconeogenesis, fatty 
acid synthesis and branched chain amino acid catabolism.  It functions as the carboxyl 
carrier for biotin-dependent carboxylases (Gravel and Narang, 2005).  Bacteria get biotin 
from two main sources, de novo synthesis (Pai and Lichstein, 1965; Gloeckler et al, 
1990; Bower et al, 1996; Flint et al, 1997) and transporter based uptake (Pai, 1973; 
Guillen-Navarro et al, 2005; Hebbeln et al, 2007).  In these systems the amount of biotin 
in the cell was controlled by transcription regulation.  A bi-functional DNA binding 
protein BirA was responsible for this function (Streaker and Beckett, 1999).  BirA was 
both a negative regulator of the biotin biosynthetic operon and also served as a biotin-
activating enzyme (Buoncristiani et al, 1986; Rodionov et al, 2002).  Separate domains 
were found to confer each function (Brennan et al, 1989).  The C. trachomatis genome 
was missing key biotin biosynthesis pathway genes.  Moreover, the DNA binding domain 
of the chlamydial birA gene was also missing.  C. trachomatis expressed the bioY gene as 
the only known uptake mechanism to obtain biotin.  The presence of a regulated 5’UTR 
might be a plausible alternative for the absence of a transcriptional regulator of biotin 
uptake.  Further experiments will shed more light on this potential riboswitch. 
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CHAPTER 4.   CHARACTERIZATION OF ncRNAs IN C. trachomatis D 
 
 
4.1 MAPPING CHLAMYDIAL ncRNA 
 
A subset of ncRNAs (10) that were detected during the discovery and validation 
phase of the study were chosen for further analysis.  They were compared to the 
previously described CTIG675 (ihtA) and the pCHL1.2 plasmid antisense transcripts.  
The selected ncRNAs included cis-acting ncRNAs (CTIG153, 270, and pCHL1.2), 
potential trans-acting ncRNAs (CTIG241, 327, 356, 498, 504, 643, and 684), and a 
potential riboswitch-like ncRNA (CTIG360). 
 
We determined the 5’ and 3’ ends of each molecule using an RNA circularization 
assay.  The RNA circularization protocol was previously developed to assess the poly-A 
status of RNAs (Urban and Vogel, 2008; Vogel and Hess, 2001).  A schematic 
representation of the procedure is shown in Figure  4-1. 
 
Briefly, total RNA of a 24 h PI sample was treated with a tobacco acid 
pyrophosphatase (to convert primary triphosphate to monophosphate groups), and 
subjected to end circularization by T4 RNA ligase.  Guided by the intergenic microarray 
results we designed primers for cDNA synthesis of circularized RNA (Table  2-1 for list 
of primers used, locate circularization primers under 5’3’ SEQ).  After cDNA synthesis, 
junction fragments were amplified by PCR (Figure  4-1), cloned, and sequenced (10 or 
more clones per reaction).  This analysis revealed the transcription start sites (TSS in 
Table  4-1) for all 12 ncRNAs, including those with more than one species (CTIG643.1/2 
and pCHL1.1/2, each pair had the same 5’ end but different 3’ ends).  The smaller 
fragment of CTIG153 could not be determined due to the constraints on primer design 
presented by the small size of transcript and extensive secondary structures. The TSSs 
determined by the RNA circularization procedure were used to predict potential 
promoters for the ncRNAs (Table  4-1).  The promoters identified were all of the σ66 
family (the major sigma factor in C. trachomatis) but functional characterization of the 
promoters was not performed and these remain predicted promoter elements at this point. 
 
 
 
Figure  4-1  A schematic representation of the RNA circularization procedure.  The 
procedure begins with the removal of the 5’ pyrophosphate using tobacco acid 
pyrophosphatase (TAP) followed by circularization using T4 RNA ligase.  Primers were 
then designed to amplify the 5’/3’ junction. 
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Table  4-1  The 5’ and 3’ ends of the ncRNAs determined in this study.   
 
 
The 5’ end is designated the TSS, the 3’ end and overall size of the ncRNAs is listed.  
Non-coding RNAs that contained non-templated additions at the 3’ end are indicated by 
an asterisk.  Promoter predictions were made by examination of the areas immediately 
upstream of the TSS.  All of the predicted promoters were of the σ66 type and two had an 
extended -10 sequence. 
 
 
 
 
 
 
 
 
Name Promoter elements (P)     -35                         -10 Arm TSS 3’end Size 
CTIG153 TTTACA TGTGATAGC N7 TGTAGA TTCAGC* 159 
CTIG241 TTTTCA TATATT N6 GGTTTA TGCTTT* 80 
CTIG270 TTTACT TCTTAT N9 AAATGT TCTAAT* 222 
CTIG327 TTGACA GATTAT N8 TTTAAG TTTTAG* 308 
CTIG356 TTTTTG TATAAC N12 AAAGTG GTAGTG 209 
CTIG360 ATGCAT TAGACT N6 AGTTTT TCATAA 241 
CTIG498 TTGTGG TCCATT N3 TCTGTA GTAACT 111 
CTIG504 TTGCTT TACAAT N6 TAGCTT GTCGTT* 73 
CTIG643.1 
TTGACA TATCAT N5 CCCGGG 
CGCAGT* 126 
CTIG643.2 GCACCT* 331 
CTIG675 TGGAAA TGTTATAAG N6 AAGTTG TGGCTT* 106 
CTIG684 TTGTAG TACGAT N6 CCAACA CTGTCT* 83 
pCHL1.1 TTGCCA TATATT N5 CATCTT 
CCCCAC* 223 
pCHL1.2 GCAAAC* 507 
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Two of the ncRNA promoters have sequences characterized as encoding “extended” -10 
regions.  All promoters had acceptable -35 sequences that ranged from 6 out of 6 matches 
to the -35 consensus [TTGACA] (CTIG327, and CTIG643), to 3 out of 6 match to 
consensus (CTIG360, CTIG498, CTIG504, and CTIG684).  Moreover all potential 
promoters had acceptable -10 elements except for 2 cases, they ranged from 5 out of 6 
ncRNAs had poor-10 elements, the match was only 2 out of 6 (CTIG327 and CTIG360). 
match to the -10 consensus [TATAAT] (CTIG365, CTIG504, CTIG643, CTIG675, and 
CHL1), to 3 out of 6 match to consensus (CTIG153, and CTIG498).  Collectively the 
combination of -10 and -35 promoter elements showed acceptable promoter strength.  
Two promoters were questionable as to whether they represent true promoters.  These 
were CTIG360 and CTIG498; both had either 3 or 2 matches to the consensus in both the 
-10 and -35 elements.  These questionable promoter elements suggested that either these 
two ncRNAs were not the primary transcript or that they represent an unusual chlamydial 
promoter that might require chlamydial RNAP holoenzyme and/or transcription factors to 
be recognized. 
 
The spacer between the -10 element and the TSS is ideally 5 to 9 nucleotides 
(Figure  1-2).  10 ncRNAs fall within this range and two were out of that range.  For 
CTIG356, the -10 element was located 12 nucleotides upstream of the TSS.  The 
promoter elements for CTIG356 were strong (5 out of 6 matches to the consensus in both 
its -10 and -35 elements).  The 12 nucleotide distance between the TSS and the -10 
element can be interpreted as a post transcriptional processing from a longer RNA and 
the native TSS might be 3 to 7 nucleotides upstream.  CTIG498 had a short spacer arm of 
3 nucleotides between the -10 element and the TSS.  Combining this observation with its 
two moderate to weak promoter elements (3 out of 6 match to the consensus), and that 
the transcript is located at the 3’end of CT497 suggests that CTIG498 might not be a 
primary transcript.  CTIG498 might be a processed transcript from the CT497 mRNA. 
 
Two promoters had extended -10 elements, namely CTIG153 and CTIG675 
(ihtA).  The predicted promoter for ihtA differed from the previously published promoter 
(Grieshaber et al, 2006). 
 
 
4.1.1 VERIFICATION OF TSS BY 5’RACE 
 
We selected 7 ncRNA to verify their TSS using 5’RACE; namely CTIG153, 
CTIG241, CTIG270, CTIG327, CTIG360, CTIG675, and CTIG684.  Primers used for 
these studies are listed in Table  2-1 under 5’RACE.  RACE can be carried out in several 
ways.  All depend on the addition of a known sequence to the 5’ end of RNA (Adaptor 
ligation) or to the 3’end of the generated cDNA (template switching reverse 
transcriptase).  We used template switching reverse transcriptase.  It was a special RT 
enzyme in that, upon reaching the 5’end of the mRNA, it acquired a terminal transferase 
activity and added three Cs to the end of the newly formed cDNA.  The newly added Cs 
formed a sticky end that allowed the end to base-pair with 3 Gs.  The sticky end base 
paired with an adapter in the reaction mixture that had 3 Gs.  The RT switched templates 
and resumed its RT activity using the adapter as its new template.  The result was a 
 52 
cDNA that had the complementary adapter sequence on its 3’ end (5’ end of the RNA).  
cDNA was amplified by PCR (gene specific primer and Universal adapter primer).  The 
template switching technique was especially beneficial as it solved one of the problems 
associated with TSS analysis.  RNA tended to acquire different secondary structures that 
required high temperatures to denature.  The elevated temperatures were inhibitory to the 
RT enzyme.  In the template switching technique the presence of secondary structure led 
to stalling of the RT, hindering the template switching and inhibiting amplification.  
When the RT enzyme reached a true 5’ end of an RNA (be it a TSS or processed product) 
it acquired a terminal transferase activity and template switching took place.  This 
technique selectively enriched for the full length cDNA rather than truncated products 
due to secondary structures.  24h PI RNA samples were DNased twice (TurboDNase, 
Ambion).  cDNA was synthesized according to manufacturers instructions (Super 
SMARTTM PCR cDNA synthesis, Clontech) using gene specific primers.  The 3’ end of 
cDNA was amplified, gel purified, cloned, and sequenced.  Results confirmed the same 
TSS determined by RNA circularization (Table  4-1). 
 
 
4.1.2 IhtA PROMOTER ANALYSIS 
 
Grieshaber et al, 2006 determined the TSS for ihtA using a primer extension 
procedure.  They determined the TSS to be 8 nucleotides downstream of the CT674 stop 
codon.  Surprisingly, when the TSS was determined using the RNA circularization 
protoccol it was determined to be 16 nucleotides downstream of the CT674 stop codon 
(Figure  4-2B).  Based on the differences in TSS, two different promoter elements were 
predicted.  To address this discrepancy several experiments were carried out.  First we 
determined the TSS using 5’ RACE and the results confirmed the TSS of ihtA in Table 
 4-1 determined by RNA circularization.  2 clones for ihtA were constructed.  ihtA was 
cloned under its own promoter (E/C in Figure  4-2A) in a promoterless vector pSMART-
HCAmp (CloneSmart® Blunt Cloning, Lucigen).  ihtA was also cloned under a 
tetracycline promoter such that its TSS would match the published TSS (E/T in Figure 
 4-2A) (for primers used see Table  2-1).  Both clones were transformed into E. coli and 
allowed to grow to OD600 of 1.  RNA was harvested (MASTERPURE, Epicentre) from 
both cultures and resolved on 10% UREA PAGE gels along with 40h PI chlamydial 
RNA.  RNA was then electrotransferred onto nylon membranes.  The blot was probed 
with an ihtA specific probe.  Analyses indicated that both chlamydial RNA and E. coli 
RNA (E/C) contained the same size band of about 100 bases.  The clone E/T showed a 
band migrating at a slightly larger size.  The Northern blot showed that ihtA could be 
transcribed from its own chlamydial promoter in E. coli.  The blot suggests that ihtA with 
the previously published TSS produced a larger product than native ihtA.  In order to rule 
out the size difference between C, E/C, and E/T were due to differences in the 3’ ends of 
the RNAs we carried out RNA circularization for both clones E/C and E/T.  The results 
verified that the 5’ end of ihtA in E/C was identical to the chlamydial ihtA.  The results 
also verified that ihtA 5’ end in E/T clone was identical to the published TSS.  Finally the 
results confirmed that the 3’ ends of all clones were identical, and the only difference 
between E/C and E/T was the difference in the predicted TSS. 
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Figure  4-2  Resolving the ihtA promoter discrepancy.  Panel A shows Northern blotting 
results.  Lane C represents chlamydial RNA, lane E/C represents RNA from E. coli 
expressing ihtA from its native promoter, and lane E/T represents RNA from E. coli 
expressing ihtA from a tetracycline promoter such that the TSS matches the published 
TSS.  Panel B represent a schematic of both promoter elements in which the red letters 
represent published promoter elements and the underlined letters represent the promoter 
as determined in this work.  (Pub: published, TSS: transcription start site). 
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4.1.3 NON-TEMPLATED ADDITIONS TO ncRNAs 
 
During mapping of the chlamydial ncRNAs, the 3’ end of each transcript was 
determined.  The 3’ ends marked with an asterisk in Table  4-1 were determined to have 
non-templated additions of variable sizes.  Table  4-2 shows a summary of the non-
templated additions to ncRNAs’ 3’ends.  For simplification, the table only includes 
individual sequences that were composed of at least 4 nucleotides detected at the 3’ end 
of RNAs.  Generally, specific transcripts had between 3-5 added nucleotides (nt) but the 
largest found was 27 nt.  Although the additions were predominantly poly-A, several 
non-templated additions contained G residues.  Upon calculating the actual percentage of 
each nucleotide in the non-templated additions we found that A represented 74%, 
followed by G (16%), then T (8.2%) and finally C (1.7%). 
 
We asked whether similar additions are present at the 3’ ends of mRNAs 
encoding ORFs.  We preformed RNA circularization assay for 5 chlamydial genes (i.e. 
CT500, CT789, CT353, CT046, and CT099).  We were able to identify the TSS for each 
mRNA but none of these mRNA had non-templated additions at their 3’ ends. 
 
 
4.2 DEVELOPMENTAL EXPRESSION OF ncRNA IN CHLAMYDIA 
 
To determine the expression patterns of ncRNAs, we chose to examine i) their 
expression during the normal developmental cycle, ii) their expression during IFN-γ-
induced persistence and reactivation, and iii) their expression during carbenicillin-
induced persistence and reactivation.  DNA/RNA samples for the developmental cycle 
were taken at 0, 3, 8, 16, 24 and 48 h PI as described previously (Belland et al, 2003b) 
and shown in Figure  4-3.  DNA/RNA was collected from IFN-γ-induced persistent 
samples at 24, 48, 72 h PI and 12, 24, 48, 72 h post reactivation (IFN and IFN R in Figure 
 4-3).  IFN-γ was used to induce persistence (5ng/ml, as determined by a pilot titration 
experiment) and was added to the media 24 h prior to infection.  Samples were 
reactivated at 24 h PI by changing media with IFN-γ-free media containing excess 
tryptophan (Belland et al, 2003a) and samples were taken at the times shown in Figure 
 4-3 (IFN and IFN R).  Carbenicillin-induced persistence was induced by the addition of 
the antibiotic (2g/ml, as determined by a pilot titration experiment) at the time of 
infection.  DNA/RNA was collected from carbenicillin-treated samples at 24, 48 h PI and 
24, 48, and 72 h post reactivation (Cb and Cb R in Figure  4-3).  As shown in Figure  4-4, 
IFN- treatment resulted in a reduction of IFUs of ca. four logs at 48 h PI.  Following 
reactivation for 48 h, the IFU values returned to ca. 98% of control cultures, indicating 
that RBs were present but were in a non-dividing or persistent state.  Similarly, 
carbenicillin treatment resulted in a distinct decrease in IFUs at 48 h PI, but following 
removal of the antibiotic (Cb reactivation), IFU numbers returned to control levels 
(Figure  4-4).  Genome copy numbers for each of the samples was determined by qPCR as 
previously described (Ouellette et al, 2006) and the samples were thoroughly DNased and 
RNA was then re-purified.  Expression of ncRNAs was determined by Northern blotting 
of RNA samples from equivalent numbers of bacteria (as determined by genomic 
normalization) for the developmental cycle and carbenicillin persistence.  Samples used  
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Table  4-2  Non-templated additions to chlamydial ncRNAs 3' ends. 
 
Name Sequence 
CTIG153 
AGAGAAA 
AAAAGTA 
AAAGTG 
AAGA 
AAAAAAA 
AAAAAAA 
AAAAA 
AAAAA 
AAAA 
AAAA 
CTIG241 
AAGAAATAAGAGAAGAG 
AGAAAATGAGAAAG 
AGGGAGAAGAAAG 
AAAAAAGGAAG 
AAAAA 
CTIG270 AAAAAAA AAAAAA 
CTIG327 
GGGAGTGGAAG 
ATTTT 
TTTT 
CTIG643-2 AAAAAAGC 
CTIG675 
GTAAAAAAAAAAACAACAAGAGACAAG 
AAATAAAAG 
GAAAGAGA 
AAAAAAA 
AAAAAAA 
AAAAAAA 
AAAAAAA 
AAAA 
AAAA 
pCHL1.1 AAGGAGCAAAAAAAA 
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Figure  4-3  Scheme of nucleic acid sample collection during chlamydial developmental 
cycle, IFN-γ-induced and carbenicillin-induced persistence and reactivation.  IFN: IFN-γ 
Persistence, Cb: Carbenicillin Persistence, R: Reactivation. 
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Figure  4-4  Titration results and establishment of persistence and reactivation.  IFN: IFN-
γ persistence, Cb: carbenicillin persistence, R: reactivation, IFU infectious units. 
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for IFN-γ persistence contained 20% of the genome numbers used for the other analyses 
due to the reduced chlamydial biomass associated with growth in the presence of IFN-γ.  
We chose to group results by ncRNAs rather than by condition, where all blots for each 
ncRNA are grouped in a single panel to allow for direct comparisons between normal and 
persistent growth conditions.  The results in Figure  4-5 show ncRNA expression patterns 
for genes that predominantly express a single transcript while those in Figure  4-6 show 
the results for ncRNAs that are expressed as multiple species (both figures also show the 
genomic-locus of each ncRNA). 
 
 
4.2.1 DEVELOPMENTAL CYCLE 
 
Expression during the normal developmental cycle showed differences between 
the ncRNAs examined in the onset and point of maximal expression of different 
transcripts, indicating that ncRNA transcription is both tightly and temporally regulated.  
Four ncRNAs showed onset of expression at ca. 8 h PI i.e. CTIG153.1/.2 (Figure  4-6A), 
CTIG356 (Figure  4-5D), CTIG360 (Figure  4-5E), and the plasmid antisense transcripts 
pCHL1.1/.2.  Seven ncRNAs were first expressed at ca. 16 h PI i.e. CTIG241 (Figure 
 4-5A), CTIG327 (Figure  4-5C), CTIG498 (Figure  4-5F), CTIG504 (Figure  4-5G), 
CTIG643.1/.2 (Figure  4-6B), CTIG675/IhtA (Figure  4-5H), and CTIG684 (Figure  4-6C).  
The cis-acting CTIG270, that overlaps the ftsI gene, was the only ncRNA that was 
expressed late in the cycle at ca. 24 h PI. 
 
 
4.2.2 IFN-γ-INDUCED PERSISTENCE 
 
Six ncRNAs (CTIG270, CTIG327, CTIG360, CTIG498, CTIG643.1/.2), and 
CTIG684) were not detectable during IFN-γ persistence.  CTIG360 (Figure  4-5E) 
resumed expression as early as 12 h after reactivation and its expression peaked at 24h 
post-reactivation.  CTIG270 (Figure  4-5B), CTIG327 (Figure  4-5C) and CTIG684 (Figure 
 4-6C) were expressed at a much reduced intensity during the first 24 h post-reactivation 
and were undetectable at later time points while CTIG498 (Figure  4-5F) and CTIG643 
(Figure  4-6B) did not appear to be expressed during reactivation. 
 
Six ncRNAs (CTIG153.1/.2, CTIG241, CTIG356, CTIG504, CTIG675, and 
pCHL1.1& (.2)) were expressed to some degree during IFN-γ persistence.  CTIG153.2 
short-form (Figure  4-6A) was expressed at a high level during IFN-γ persistence, while 
expression of the longer form (CTIG153.1) declined rapidly.  During reactivation, both 
forms declined at approximately the same rate and by 48 h PR they were no longer 
detectable.  CTIG241 (Figure  4-5A), CTIG356 (Figure  4-5D), CTIG675 (Figure  4-5H), 
and the plasmid antisense pCHL.1/.2 (Figure  4-6D) were expressed at low levels during 
IFN-γ persistence but showed increased expression levels following reactivation.  
CTIG504 (Figure  4-5G) was expressed at ca. the same level throughout IFN-γ-induced 
persistence and reactivation. 
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Figure  4-5  Developmental expression of ncRNAs in C. trachomatis during the 
developmental cycle, IFN-γ-induced and carbenicillin-induced persistence and 
reactivation.  Each panel (A-H) shows the expression pattern of the particular ncRNA 
under the conditions described in Figure  4-3.  In addition the genomic position of 
ncRNAs is shown in the schematic panel; black arrowheads represent ncRNAs, while 
gray arrowheads represent tRNA. 
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Figure  4-6  Developmental expression of the processed forms of ncRNAs in C. 
trachomatis during the developmental cycle, IFN-γ-induced and carbenicillin-induced 
persistence and reactivation.  Each panel (A-D) shows the expression pattern of the 
particular ncRNA under the conditions described in Figure  4-3.  In addition the genomic 
position and orientation of the ncRNAs are shown in the schematic panel under the 
developmental cycle panel. 
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4.2.3 CARBENICILLIN-INDUCED PERSISTENCE 
 
In contrast to the situation with IFN-γ-induced persistence, virtually all tested 
ncRNAs showed significant expression during carbenicillin treatment.  The exception 
was CTIG270 (Figure  4-5B), which was undetectable during carbenicillin treatment and 
was transiently expressed 24 h after reactivation. 
 
Nine ncRNAs (CTIG153.1/.2), CTIG327, CTIG356, CTIG360, CTIG498, 
CTIG643.1, CTIG675, CTIG684, and pCHL1.1) showed a decline in expression as the 
infection progressed from 24 h PI to 48 h PI.  This decline in expression ranged from a 
slight reduction to complete disappearance of the transcripts, as evident with CTIG498 
(Figure  4-5F), CTIG684 (Figure  4-6C), and pCHL1.1 (the longer plasmid antisense 
transcript, Figure  4-6D).  In contrast, the only ncRNA to show a marked increase in 
transcript levels during carbenicillin treatment was CTIG643.2 (the longer transcript, 
Figure  4-6B).  Two ncRNAs showed little change in transcript levels during persistence 
(CTIG241; Figure  4-5A, and pCHL1.2; Figure  4-6D).  Transcript levels for virtually all 
of the tested ncRNA were detectable 24h post-reactivation.  Many of these declined to 
the point at which they could not be detected at 48h post-reactivation (CTIG153.1& (.2), 
CTIG270, CTIG327, CTIG360, CTIG684, and pCHL1.1) while the rest declined to some 
degree as the reactivation progressed from 24 to 72 hours.  CTIG498 (Figure  4-5F) was 
the exception at it was not detected during the course of reactivation from carbenicillin 
treatment. 
 
 
4.3 DISCUSSION 
 
 
4.3.1 RNA CIRCULARIZATION TECHNIQUE 
 
We used an RNA circularization technique for mapping ncRNAs.  The technique 
offered a reliable and cost effective method that determines both the 5’ and 3’ ends of 
RNA.  Moreover, this technique was successful at identifying 3’ non templated additions.  
RNA circularization was used to identify the ends of 11 mRNAs and rRNAs of the 
mitochondrial genome of Drosophila melanogaster (Stewart and Beckenbach, 2009).  It 
was also applied in a protocol termed “ligation-mediated PCR” allowing the detection 
and mapping of cleavage products of specific nucleic acid molecules out of complex 
nucleic acid mixtures (Grange, 2008).  Moreover, the RNA circularization technique was 
also used to monitor the editing processes that result in the structural retailoring of the 
aminoacyl acceptor stems of mitochondrial tRNAs (Lohan and Gray, 2007).  From these 
examples and others, it is clear that RNA circularization is a reliable technique for 
mapping RNA ends. 
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4.3.2 POTENTIAL PROMOTER ELEMENTS FOR ncRNAs 
 
In E. coli the consensus arrangement for the major sigma factor is shown in 
Figure  1-2 (reviewed in Ross and Gourse, 2009).  Although there appear to be 
considerable levels of homology between C. trachomatis σ66 and E. coli σ70, Mathews 
and Sriprakash reported that chlamydial RNA polymerase can tolerate considerably more 
variation at the -10 and -35 regions (Mathews and Sriprakash, 1994).  In general, most 
published σ66 promoter elements have acceptable variation from the consensus (Engel and 
Ganem, 1987; Birkelund et al, 1989; Douglas and Hatch, 1995, 1996; Ochiai et al, 1999; 
Shen et al, 2000; Schaumburg and Tan, 2003; Grech et al, 2007).  Therefore; except for 
CTIG360 and CTIG498, the predicted promoters are σ66 promoters. 
 
Two of the predicted promoters had extended -10 characteristics.  Extended –10 
promoter elements are present in ~20% of all E. coli genes (Burr et al, 2000).  The 
primary σ factor (σ70) has four regions of similarity.  It is known that residues in region 2 
recognize a −10 element (TATAAT) (Murakami et al, 2002), residues in region 3 
recognize an extended TGn −10 element (positions −15 to −13) (Barne et al, 1997), and 
residues in region 4 recognize a −35 element (TTGACA) (Campbell et al, 2002).  
However, not all three of these promoter elements need to be present for promoter 
function.  E. coli σ70-dependent promoters have typically been characterized as either 
−10/−35 promoters, which have good matches to both the canonical −10 and −35 
sequences and do not require the TGn motif (McClure et al, 1983), or as extended -10 
promoters (TGn/-10 promoters) which have the TGn motif and an excellent match to the 
-10 consensus sequence and do not require a -35 element (Kumar et al, 1993; Lisser and 
Margalit, 1993; Browning and Busby, 2004).  In E. coli, extended -10 promoters have 
several characteristics, Extended -10 promoters, tend to have longer spacer (distance 
between -10and -35 elements) lengths than promoters that do not.  They also tend to show 
fewer matches to the canonical -35 elements (Mitchell et al, 2003).  More importantly 
open promoter complexes can be formed on an extended -10 promoter at temperatures as 
low as 6°C a temperature at which complexes on most promoters are closed (Minakhin 
and Severinov, 2003). 
 
The TSSs in Table  4-1 predict 2 potential extended -10 promoters, CTIG153 and 
ihtA.  Similar to σ70 in E. coli, chlamydial σ66 needs only regions 2 and 3 to interact with 
extended -10 promoters.  A large and diverse family of proteins known as “anti-σ factors” 
regulates utilization of particular classes of bacterial promoters by targeting specific σ 
factors (Helmann, 1999; Hughes and Mathee, 1998).  Typically, anti-σ factors interact 
with core binding determinants in their cognate σ factors, thereby preventing their 
association with the RNAP core enzyme (Campbell et al, 2008).  The AsiA protein of 
bacteriophage T4 is one of the earliest anti-σ factors to be identified.  It targets σ70 (Orsini 
et al, 1993; Severinova et al, 1996), however, unlike most other well-characterized anti-σ 
factors, AsiA binds to σ70 primarily through an interaction with σ70 conserved region 4.2 
which has also been implicated in sequence-specific recognition of the -35 consensus 
promoter element (Severinova et al, 1998; Yuan et al, 2009).  As a component of the σ70-
containing holoenzyme, AsiA inhibits transcription from the -10/-35 class of promoters, 
but does not inhibit transcription from extended-10 promoters (Severinova et al, 1998).  
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Interestingly, CT663 interacts with the flap domain of the β subunit (beta-flap) of RNA 
polymerase core enzyme, and the conserved region 4 of the primary sigma subunit σ66 in 
C. trachomatis.  CT663 inhibits σ66-dependent transcription in vitro (Rao et al, 2009).  
Thus there is a possibility that CT663 may have a role in regulating transcription of TGn 
and nonTGn promoters. 
 
 
4.3.3 NON-TEMPLATED ADDITIONS ON THE 3’ENDS OF ncRNA 
 
It has been shown that prokaryotes posses two enzymes that can add nucleotides 
to the 3’ ends of RNA without a template, namely Poly(A) polymerase I (PAPI) (Paschal 
et al, 2008) and Polynucleotide phosphorylase (PNPase) (Grunberg-Manago et al, 1955).  
Both enzymes are involved in modulating RNA stability (Carpousis et al, 1999); 
(Carpousis et al, 2008).  PAPI, adds poly(A) extensions to the 3′ ends of mRNAs, as well 
as to tRNA and rRNA (Li et al, 1998).  PNPase on the other hand, adds long, 
heteropolymeric tails in vivo (Mohanty and Kushner, 2000).  Polyadenylation of RNAs 
by PAPI in E. coli plays a significant role in mRNA decay and general RNA quality 
control (Jasiecki and Wegrzyn, 2003; Mohanty and Kushner, 2006).  Chlamydial 
genomes contain 2 paralogues of PAPI (CT410 and CT704) and one PNPase (CT842).  
We believe that the observed non-templated tails are due to the activities of these 
enzymes.  The tails composed of only As are probably due to the activity of PAPI, while 
the heteropolymeric tails are probably due to the activity of PNPase.  In either case the 
modified RNA represent an intermediate for degradation.  The heteropolymeric tails in 
Chlamydia were shown to contain the different nucleotides according to the following 
preference A > G > U > C.  The same preference was also observed for E. coli PNPase 
(Mohanty et al, 2000). 
 
Regulation of ncRNAs by polyadenylation was well characterized in the 
glmS/glmZ/glmY system (Kalamorz et al, 2007; Reichenbach et al, 2008).  Translation of 
the glmS mRNA was normally weak since an internal hairpin structure containing the 
glmS Shine Dalgarno sequence limits ribosome access to the downstream glmS RBS and 
therefore GlmS synthesis (Kalamorz et al, 2007; Urban et al, 2008).  glmZ, an ncRNA, 
functions as an anti-antisense and melts this hairpin, allowing glmS translation.  glmZ is 
unstable and its stability is greatly increases by glmY, another ncRNA.  Thus the levels of 
GlmS are affected by glmZ, which in turn is affected by glmY (Kalamorz et al, 2007).  
glmY levels are controlled by polyadenylation and it was found that about 50% of glmY is 
polyadenylated.  This regulatory hierarchy signifies the effect of polyadenylation on the 
function of glmS/glmZ/glmY (Urban et al, 2008) reviewed in (Gorke and Vogel, 2008). 
 
 
4.3.4 ncRNA EXPRESSION UNDER BOTH NORMAL AND STRESS 
CONDITIONS 
 
The ncRNAs shown in this study may represent a subset of the total C. 
trachomatis ncRNAs since initial identifications were done using RNA from late stage 
infection (40h PI).  For example, ncRNAs that were only expressed during the early 
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stages of the developmental cycle were not tested.  The technical difficulties associated 
with obtaining sufficient RNA from early stages of the developmental cycle have 
hindered this approach.  Most of the ncRNAs showed a decrease in expression during the 
late stages of the developmental cycle, a point in which the predominant developmental 
forms are the infectious, non-metabolizing EBs. 
 
As is the case with many ncRNAs, their expression is tightly controlled.  Their 
might be a significant portion of chlamydial ncRNAs that are not induced under normal 
developmental conditions but could be induced under various stress conditions.  Thus it 
may be worthwhile to catalogue stress-induced ncRNAs, after establishing the 
appropriate system to screen their functions. 
 
The predicted target of CTIG270 is the ftsI transcript encoding FtsI.  FtsI in other 
bacteria is associated with peptidoglycan modification during cell division.  CTIG270 
was the only ncRNA to show late onset of transcription (24h PI).  At this time chlamydial 
inclusions are easily visible under the microscope and some EBs can be seen inside 
inclusions.  This timing of expression reinforces the hypothesis that this RNA controls 
ftsI mRNA, as one of the hallmarks of RB to EB differentiation is the inhibition of cell 
division.  For further discussion concerning CTIG270 and ftsI, please refer to section 
 5.2.1 below. 
 
One of the interesting ncRNAs was CTIG643.1&.2 (long and short transcript 
respectively) as there is a significant difference in expression between the normal 
developmental cycle and carbenicillin treatment.  The sequence of CTIG643.2 shows a 
rho independent terminator marking its 3’ end.  During the developmental cycle the rho 
independent terminator was not functional and the major transcript detected was the 
longer transcript (CTIG643.1).  During carbenicillin treatment, RNA polymerase 
terminated efficiently at the rho independent terminator producing primarily CTIG643.2.  
This interesting phenomenon can be interpreted in two ways.  Either the RNA 
polymerase enzyme became increasingly sensitive to termination during carbenicillin 
treatment or there is a factor that bound the RNAP and prevented its termination during 
the normal developmental cycle.  This factor might be unavailable during persistence.  
The C. trachomatis genome encodes three factors involved in termination/anti-
termination; NusA (CT097), NusG (CT320), and GreA (CT636).  NusA is an essential 
multifunctional transcription elongation factor that is universally conserved among 
eubacteria and archaea (Nudler and Gottesman, 2002).  NusA may elicit opposite effects 
on transcription (Richardson, 1996).  By itself, NusA stimulates pausing at some hairpins 
and rho-independent terminators.  In complex with other Nus factors (e.g. NusG) it 
stimulates anti-termination at both rho-dependent and rho-independent terminators 
(Richardson, 1996; Nudler et al, 2002).  GreA, functions when transcription elongation 
slows or stops completely at certain points of the template, resulting in formation of 
paused or arrested complexes.  In these complexes, RNAP shifts along the DNA template 
in the direction opposite to that of transcription (Komissarova and Kashlev, 1997; Nudler 
et al, 1997).  As a result, the 3' end of RNA disengages from the RNAP catalytic center 
making further elongation impossible.  An arrested complex can resume transcript 
elongation only following endonucleolytic cleavage of the nascent RNA that generates a 
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new 3' end of the transcript in the RNAP catalytic center.  The endonucleolytic reaction 
performed by the RNAP catalytic center is slow, but is greatly stimulated by transcript 
cleavage factors including GreA (Fish and Kane, 2002; Sergei et al, 2005; Stepanova et 
al, 2007).  A recent study of iron induced persistence in C. trachomatis E showed that 
both NusA and NusG were regulated (Dill et al, 2009).  This study is intriguing as it 
shows that Nus factors are regulated during persistence and might explain why CTIG643 
shows such discrepancy in termination under normal and stress conditions. 
 
CTIG360 was described earlier as a potential riboswitch for the bioY gene.  
CTIG360 was expressed early during the normal developmental cycle and was also 
detected during carbenicillin treatment.  It was not detected during IFN-γ-induced 
persistence but its expression was readily detected during reactivation.  IFN-γ induced 
persistence analyses indicated that, although CTIG360 was not detected, a larger product 
(> 500 nt) was detected.  The bioY gene is ca. 785 bp, including its 5’UTR.  There is a 
possibility that this band represented the full length bioY mRNA.  Chlamydia is a biotin 
auxotroph and might be sensing a need to transport biotin under IFN-γ treatment, thus 
allowing for more full length transporter gene to be transcribed.  Under normal growth 
conditions there may be enough biotin that the transporter is down-regulated.  This 
hypothesis needs more testing to verify such claims.  We are currently undergoing 
detailed experiments using E. coli lacking bioY function to verify the function of the 
chlamydial bioY ortholog and to test the riboswitch hypothesis. 
 
 
4.3.5 SIGNIFICANCE OF MULTIBLE BANDS FOR A SINGLE ncRNA 
 
The expression of multiple species of ncRNAs has been previously described (e.g. 
for gadY, (Opdyke et al, 2004), dsrA (Repoila and Gottesman, 2001), and glmY 
(Reichenbach et al, 2008)) and is believed to involve post-transcriptional processing that 
is dependent on the balance between protection by RNA binding protein(s) and 
degradation by RNases.  The functional significance has not been well-studied but, 
importantly, Davis and Waldor (Davis and Waldor, 2007) have shown that MicX of 
Vibrio cholerae can be detected as both an active precursor and a processed form and that 
the smaller, processed molecule is significantly more stable and abundant.  Interestingly, 
processing occurs in an Hfq and RNase E-dependent manner but the regulatory effects of 
MicX on its target mRNA is not dependent on Hfq.  Chlamydia spp. do not contain 
obvious orthologs of Hfq or RNase E, suggesting that regulation and processing may be 
very different in these organisms.   
 
The presence of several bands representing a single ncRNA occurs because the 
ncRNA is processed (CTIG153, pCHL1) or the ncRNA might incompletely terminate at a 
rho independent terminator (CTIG643).  The relative abundance of each band on the 
Northern blotting followed two different kinetic profiles (Figure  4-6).  One profile shows 
identical relative intensities of both bands representing a single ncRNA.  This group is 
represented by (CTIG153, pCHL1, CTIG643, and CTIG684) under normal developmental 
condition.  The second profile shows different relative intensities, e.g. under carbenicillin 
treatment the small band was dominant for CTIG153, CTIG643 and pCHL1.  Previous 
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discussion of CTIG643 indicated a likely mechanism, but for CTIG153 and pCHL1 there 
is no terminator in either RNA.  Multiple bands in CTIG153 and pCHL1 might be due to 
processing of the 3’ end as both ncRNAs are antisense transcripts and the short 
transcripts represent the 5’ half of the molecule.  Apparently the 3’ end of the molecule 
was cleaved after forming double stranded RNA with the target gene.  Processing of 
double stranded RNA may be carried out by chlamydial RNase III (CT297) and/or RNase 
G (CT808).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 67 
CHAPTER 5.   FUNCTIONAL ANALYSIS OF ncRNA 
 
 
5.1 CIS-ACTING CTIG270 
 
 
5.1.1 VERIFICATION OF CTIG270 MAPPING 
 
One of the cis-acting ncRNAs (CTIG270) (Figure  3-1) was selected for further 
analysis.  Mapping of CTIG270 transcript was carried out using the RNA circularization 
protocol (Table  4-1).  CTIG270 extends on the upper strand 142 and 80 nucleotides 5’ 
and 3’ to the ftsI stop codon respectively (Table  4-1).  Mapping was verified using 5’ 
RACE using C. trachomatis RNA from 24h PI (Super SMARTTM PCR cDNA synthesis, 
Clontech).  The amplified 5’RACE product was TA cloned into pCR2.1 (Invitrogen, CA) 
and individual clones sequenced.  Results identified a TSS for CTIG270 similar to what 
was reported in (Table  4-1). 
 
 
5.1.2 FUNCTIONAL ANALYSIS OF CTIG270 IN A SURROGATE SYSTEM 
 
To test the effect of expression of CTIG270 on ftsI, a system was constructed 
where both ftsI and CTIG270 were cloned in two compatible medium copy number 
plasmids and transformed into E. coli.  ftsI was fused in frame to a 5’ FLAG-tag sequence 
(N-DYKDDDDK-C) and cloned under the control of a lac promoter (from pCR2.1, 
Invitrogen). 
 
When CTIG270 was induced (Figure  5-1 lane 1 panel C) neither the FLAG-ftsI 
protein nor its mRNA were detected (Figure  5-1 lane 1 panel A, B).  When the second 
inducer was added (Figure  5-1 lanes 2 and 3), the FLAG-ftsI protein and its mRNA were 
undetectable.  The amount of CTIG270 detected was reduced by the end of the double 
induction period and none of the RNAs or protein was detectable (Figure  5-1 lane 3). 
 
When the expression of the FLAG-tagged ftsI was induced by IPTG; both the 
mRNA and protein were detectable (Figure  5-1 lane 4).  When the second inducer was 
added (Arabinose) CTIG270 was detected and both FLAG-ftsI protein and its mRNA 
were transiently increased (Figure  5-1 lane 5).  By the end of the double induction period, 
the FLAG-ftsI protein and its mRNA were barely detectable, and CTIG270 was markedly 
reduced (Figure  5-1 lane 6). 
 
The control culture (no induction) showed little to no expression (Figure  5-1 lane 
7).  When both inducers were added both RNAs and the protein were detected (Figure 
 5-1 lane 8).  By the end of the co-induction experiment the FLAG-ftsI protein and its 
mRNA were not detectable and reduced amounts of CTIG270 were detectable. 
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Figure  5-1  CTIG270 analysis in an E. coli surrogate system.  Lanes 1, 2, 3 represent 
induction by arabinose followed by IPTG, lanes 4, 5, 6 represent induction by IPTG 
followed by arabinose, lane 7 represents no induction, lanes 8, 9 represent double 
induction.  Panel A showed Western blotting for a FLAG tagged ftsI, Panel B showed 
Northern blotting for ftsI mRNA, Panel C showed Northern blotting for CTIG270.  Ara: 
arabinose. 
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5.1.3 IN-VIVO EXPRESSION OF CTIG270 AND ftsI 
 
We analyzed the expression of both CTIG270 and ftsI using matched Northern 
blotting and reverse transcription-PCR respectively.  The expression of ftsI mRNA 
reached its maximum 16h PI.  On the other hand, CTIG270 was barely detectable at the 
same time point (Figure  5-2).  By 24h PI, CTIG270 expression reached its maximum 
while ftsI expression level was steadily decreasing.  By 48h PI, both RNAs were barely 
detectable. 
 
 
5.2 DISCUSSION 
 
 
5.2.1 USING E. coli AS A SURROGATE SYSTEM 
 
We used an E. coli surrogate expression system because we lack an established 
genetic system to manipulate Chlamydia.  The results show possible mechanisms of 
action that might take place in vivo during an actual infection.  The results must be 
understood in the contexts of an actual chlamydial infection (in a monolayer or in clinical 
samples).  Knowing that both E. coli and Chlamydia are different and knowing that E. 
coli has the RNA chaperone Hfq, while Chlamydia lacks this protein, we examined the 
results. 
 
The matched RT-PCR/Northern results for ftsI/CTIG270 (Figure  5-2) show the 
levels of both species of RNA in vivo.  When the expression of ftsI was at its maximum 
level, the expression of CTIG270 was undetectable.  On the contrary, when the 
expression of CTIG270 reached its maximum level ftsI mRNA level was rapidly 
declining.  This pattern is suggestive of an antisense regulation system, and it adds an 
indirect in vivo validation for results obtained from the surrogate system. 
 
It has been shown that Arabinose can act as an inducer for lac derived promoters 
in E. coli (Narayanan et al, 2006).  This is evident in Figure  5-1 lanes 5 which showed a 
transient increase in the FLAG-FtsI protein and RNA under arabinose induction.  This is 
why we switched from using lac promoters to tetracycline promoters in later experiments 
(described later). 
 
 
5.2.2 EXPRESSION OF CTIG270 DURING STRESS CONDITIONS 
 
The results of the surrogate expression system showed an efficient tight regulation 
of the FLAG tagged ftsI.  CTIG270 controlled the expression of its target gene whether it 
was induced before or after target gene induction.  In Figure  5-1 lanes 3, 6, and 9, both 
inducers were present and both RNAs were transcribed.  Interestingly we could not detect 
either the FLAG-FtsI protein or its mRNA and very little CTIG270 was detected.  This 
result helped us to interpret the CTIG270 expression pattern during IFN-γ persistence 
(Figure  4-5 panel B).  The expression of CTIG270 was greatly reduced during IFN-γ  
 70 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  5-2  RT-PCR of ftsI mRNA and CTIG270 Northern blotting during normal 
developmental cycle.  EB: elementary bodies (time zero). 
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treatment.  IFN-γ-induced persistence was associated with a block in RB cell division and 
the presence of large, multinucleate RBs within the inclusion (Beatty et al, 1993).  The 
lack of CTIG270 signal during IFN-γ-induced persistence implied that either the ncRNA 
was not transcribed or that the ncRNA is binding to its target and is being rapidly 
degraded by RNase.  The idea appears radical, but if the function of CTIG270 was to 
quantitatively degrade its target mRNA then the lack of signal on the Northern blotting 
might be because the ncRNA is highly active.  CTIG270 may be playing a role in the lack 
of bacterial cell division.  C. trachomatis, although lacking Hfq and RNase E, encodes a 
homolog of RNase III which, among other functions, can degrade dsRNA (Viegas et al, 
2007).  To test this phenomenon we may need to genetically control the expression of ftsI 
inside Chlamydia and measure the effect on CTIG270 transcript half life at various time 
points. 
 
During carbenicillin treatment CTIG270 was not detected and treatment with 
carbenicillin and other β-lactams results in very large, aberrant RBs that appear to have a 
distinct block in cell division.  However, in this case the situation is somewhat different 
as FtsI (a penicillin binding protein) is also a target of carbenicillin.  In other words, FtsI 
is already under tight functional control from the antibiotic.  In summary, the delayed 
expression of CTIG270 and then the complete disappearance of the ncRNA during 
persistence fits with our hypothesis that CTIG270 is regulating ftsI mRNA. 
 
 
5.3 DESIGN AND OPTIMIZATION OF A SCREENING TOOL FOR trans-
ACTING ncRNA 
 
 
5.3.1 RATIONAL 
 
Screening the chlamydial genome for potential ncRNA targets was a novel goal.  
We proposed several criteria for designing a screening system.  These criteria were 
pivotal so that the system would be functional and useful: 
 
 Genomic DNA fragments will be cloned in a translational fusion with a reporter 
system (target plasmid).  Upon inhibition of translation a phenotype can be 
visually detected. 
 
 The phenotype elicited by translational inhibition of the reporter system should be 
easily distinguished.  This phenotype should allow selection of positive clones 
from a larger number of negative background clones. 
 
 During transformation, E. coli that takes up a self-ligated plasmid would not 
survive phase I selection, thus reducing plasmid load. 
 
 Target plasmid with library inserts that are out of frame with the reporter system 
would not survive phase I selection.  Phase I selection will reduce the genomic 
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fragments under test to include only genomic fragments in frame with the reporter 
system. 
 
 Target plasmid should be a low or medium copy plasmid. 
 
 Plasmid carrying the ncRNA (effector plasmid) should be a high copy plasmid 
compatible with the target plasmid. 
 
 Expression of both the genomic DNA/reporter system and the ncRNA should be 
controllable. 
 
We designed a screening system that would fulfill these criteria.  The system 
underwent an optimization process until a target plasmid was constructed that adequately 
fulfilled the aforementioned criteria. 
 
We used the pZ modular plasmid system designed by Lutz and Bujard (Lutz and 
Bujard, 1997).  The pZ vector comprised of three main modules separated by unique 
cleavage sites.  The modular organization of the plasmid made it easy to exchange 
promoters, origins of replication, and RBS.  We used plasmid pZS*24MCS (Figure  5-3) 
as the parent plasmid, this plasmid had origin of replication SC101* (3-5 plasmid copy 
numbers/cell) (Manen et al, 1994) and had Kanamicin as a selectable marker.  Module I 
contained the promoter/operator construct, and ribosomal binding site (RBS).  This 
module was flanked by AatII/EcoRI.  Module II harbored one of several compatible 
origins of replication (ColE1, p15A, pSC101*).  This module was flanked by AvrII/SacI.  
Module III contained one of five antibiotic resistance markers for our purpose we used 
Kanamicin resistance marker. 
 
 
5.3.2 SCREENING SYSTEM DESIGN 
 
Target plasmid: in order to construct the target plasmid, we used life/death as a 
selection tool.  Life/death selection was used for phase I selection which involved 
elimination of non-translational fusions and self ligations.  Life/death selection was also 
used in phase II selection which involved selection of potential targets for ncRNA.  
 
Life/death selection was established by using a fusion between a positive 
selection gene and a negative selection gene.  The positive selection gene was an 
antibiotic marker, (chloramphenicol acetyltransferase (CAT)).  The negative selection 
gene was a toxic gene (ccdB).  ccdB is a member of the ccd poison/antidote system of the 
F plasmid (Critchlow et al, 1997; Maki et al, 1996).  This system encodes a toxin 
targeting the essential E. coli DNA gyrase.  CcdB inhibits DNA gyrase leading to 
unrepaired strand breaks and disintegration of the bacterial chromosome.  CcdA, On the 
other hand, is the antidote, it interacts with CcdB protein to neutralize its toxicity 
(Bahassi et al, 1999).  This toxin-antitoxin system was explored by other investigators 
(Gabant et al, 1997), and ccdB gene is in use in the Invitrogen Gateway systemTM.  The 
reporter system was a translational fusion between ccdB and CAT (ccdB-CAT). 
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Figure  5-3  Vector pZS*24MCS.  The vector had Plac/ara promoter, flanked by 
AatII/EcoRI, the map also shows pSC101* origin of replication flaked by AvrII/SacI. 
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The fusion gene was under a PLtetO-1 promoter (Lutz et al, 1997).  Figure  5-4 
represents a schematic of the fusion gene.  ccdB was cloned with no translational signal 
(RBS and the first ATG) at the 5’ end.  The absence of a translational signal upstream of 
the fusion genes prevented the ribosomes from binding to the newly formed mRNA.  
When the fusion gene was transcribed the cells maintained their sensitivity to 
chloramphenicol.  The fusion gene was constructed as follows: briefly ccdB and CAT 
were amplified separately by PCR using the Gateway Vector Conversion System as a 
template (Invitrogen, CA).  Sequential PCR reactions were used to add the PLtetO-1 
promoter sequence along with a StuI site directly upstream of ccdB second codon.  PCR 
was also used to create a 15-base overlap between ccdB 3’ end and the CAT 5’ end.  
During primer design the first ATGs of both ccdB and CAT were eliminated along with 
ccdB stop codon.  The 15-base overlaps between ccdB and CAT were designed to keep 
both genes in frame after recombination.  PCR products were gel purified and 
recombined using PCR InFusion Cloning kit (Clontech, CA) according to manufacturer’s 
instructions.  The recombination product was selected and amplified using appropriate 
PCR primers.  PCR was used to create 15 base overlaps between the fusion gene and the 
linearized target plasmid.  Plasmid pZS*24MCS was digested with AatII/EcoRI (NEB, 
MA) to remove the promoter, RBS, and the multiple cloning site (MCS).  The ccdB-CAT 
fusion PCR amplicon was gel purified and recombined with the linearized pZS*24MCS 
plasmid using PCR InFusion Cloning kit (Clontech, CA).  The recombined plasmid was 
transformed into electrocompetent One Shot ccdB Survival Cells (Invitrogen, CA).  The 
ccdB Survival cells were used because they were resistant to the cytotoxic effect of CcdB 
protein.  These cells had a mutation in the gyrA gene (Arg462/Cys substitution) (Bernard 
and Couturier, 1992; Bernard et al, 1993).  Transformants were selected on LB agar 
Kanamicin plates (25µg/ml).  For list of primers see Table  2-1 under ccdB/CAT Cloning.  
The fusion gene lacked a translational start signal.  For the fusion gene to be translated it 
required an in frame translational signal supplied by the chlamydial genomic library.  E. 
coli where the fusion protein was produced were chloramphenicol resistant, while E. coli 
where the fusion protein was not produced were chloramphenicol sensitive. 
 
 
5.3.3 FUNCTIONAL TESTING OF THE TARGET PLASMID 
 
Testing the target plasmid was carried out by supplying a translational signal to 
ccdB-CAT fusion gene.  This was followed by investigating whether the resulting plasmid 
confers chloramphenicol resistance to ccdB resistant E. coli (positive selection) and 
whether it subjects ccdB sensitive E. coli to ccdB mediated killing (negative selection). 
 
 
 
Figure  5-4  Initial design of the fusion reporter system. 
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To carry out this test, target plasmid was linearized by StuI digestion (NEB, MA).  The 
translational signal was supplied by hctA leader/ATG.  hctA leader sequence was 
amplified by PCR and the amplicon included all the 5’UTR of hctA plus the first ATG 
(Fahr et al, 1995) (Table  2-1 under Test SEQ Cloning).  PCR was also used to add 15 
base overlaps with both ends of the StuI linearized plasmid as shown in Figure  5-5.  The 
resulting plasmid was transformed into electrocompetent One Shot ccdB Survival Cells 
and selected on Kanamicin (25µg/ml)/chloramphenicol (12.5µg/ml) LB Agar plates.  
Clones were screened by PCR and confirmed by sequencing.  ccdB Survival cells 
containing translatable fusion gene were resistant to chloramphenicol.  This implied that 
the fusion gene was translated and cells acquired chloramphenicol resistance phenotype.  
The Target plasmid containing translatable fusion gene was transformed into ccdB 
sensitive cells (Bl21A1 E. coli, Invitrogen) and grown on Kanamicin/chloramphenicol 
LB agar plates.  Cells survived this selection.  The lack of lethal effect of CcdB was not a 
result of lack of translation of the fusion gene but rather CcdB in the fused form might 
not be functional. 
 
 
5.4 REDESIGN OF THE TARGET PLASMID 
 
To address the loss of function of CcdB in the fusion form, we decided to insert 
two protease cleavage sites flanking ccdB.  Upon translation of the fusion gene, a 
protease will regenerate the native CcdB.  
 
Many proteases were used to cleave fusion proteins.  For example, activated 
blood coagulation factor X (factor Xa), enteropeptidase (enterokinase) and α-thrombin 
have been used.  There are many reports of fusion proteins that were cleaved by these  
 
 
 
 
Figure  5-5  Schematic of the PCR infusion cloning. 
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proteases at locations other than the designed site (Forsberg et al, 1992; Forsberg et al, 
1991; He et al, 1993; Stevens, 2000; Wagner et al, 1996), We selected tobacco etch virus 
protease (TEV protease) (Carrington and Dougherty, 1987, 1988) for use in the target 
plasmid, as the TEV protease had higher stringent sequence specificity than many other 
proteases (Dougherty et al, 1989; Kapust et al, 2002), it was already in use to cleave 
fusion proteins in vivo (in E. coli) (Shih et al, 2005) and in vitro for affinity purification 
(Babu et al, 2009; Song et al, 2009).  TEV protease cleaves the amino acid sequence 
ENLYFQG/S between QG or QS with high specificity (Parks et al, 1994).  Cleavage by 
TEV protease leaves one amino acid at the N-terminus of the protein of interest (Kapust 
et al, 2002).  The use of the TEV protease presented two problems.  The first problem 
was the low solubility of the protein in E. coli (Rachel and David, 1999).  The second 
problem was the auto-digestion of the protease yielding fragments of very low activity 
(Lucast et al, 2001).  We selected TEV protease developed by van den Berg et al, 2006.  
The group used TEVS219N first created by Lucast et al, 2001.  The single amino acid 
change, S219N inhibited the auto-proteolysis and subsequent loss of activity of the 
protease.  The group then embarked on an accelerated mutagenesis scheme to develop a 
mutated version of the TEV protease that had more solubility than the wild-type protein.  
They developed a mutated TEV protease that was 5 times more soluble than the wild-type 
but retained wild-type levels of proteolytic activity.  The mutant TEVsh had 3 amino acid 
changes from the wild-type (van den Berg et al, 2006). 
 
Analysis of the crystal structure of both CcdB (Dao-Thi et al, 2004; Loris et al, 
1999) and CAT (Andreeva et al, 2000) showed that a cleavage site between CcdB and 
CAT might be hidden from the protease.  To address this potential problem we adopted a 
technique termed “Target-directed proteolysis at the ribosome” developed by Henrichs et 
al, 2005.  Henrichs et al. developed a technique for SecA inactivation by proteolysis in 
vivo.  Originally a technique called target-directed proteolysis allows complete 
proteolytic inactivation of target proteins in vivo (Mondigler and Ehrmann, 1996).  When 
investigating Target-directed proteolysis sites in SecA, it was found that lack of complete 
accessibility and protein folding caused the TEV cleavage site located downstream of 
residue 195 to be incompletely cleaved (Mondigler et al, 1996).  Henrichs et al. devised a 
way to tether the TEV protease to the ribosome.  The tethered TEV protease gained 
access to the nascent polypeptide as it exited the ribosome before folding occurs.  The 
technique was successful at getting complete cleavage of the target protein (Henrichs et 
al, 2005).  The tethering motive was cloned from an E. coli trigger factor (tig). Previous 
research showed that E. coli tig had a binding site on ribosomes (Hesterkamp et al, 1997).  
The domain that retained the ribosomal tethering activity was the N terminal 144 
residues.  Henrichs et al, 2005 fused this domain to the N terminus of TEV protease and 
the result was complete cleavage of SecA195.  We adopted the same strategy and fused 
tig144 to the TEVsh protease. 
 
TEVsh protease gene was put under the control of a Plac/ara-1 promoter (Lutz et al, 
1997), which was a synthetic fusion of a lac promoter and an arabinose promoter.  This 
synthetic promoter was regulated over a ~1800-fold range whereby derepression via 
IPTG caused a ~100-fold induction.  Activation with arabinose caused a 15-20-fold 
 77 
increase in promoter activity (thus both inducers lead to 1500-2000 fold activation) (Lutz 
et al, 1997). 
 
We prepared four clones, all of them had the fused gene ccdB/CAT under the 
control of a PLtetO-1 promoter and all four clones had two TEV protease cleavage sites 
(tev) flanking ccdB (The fusion gene is now tev-ccdB-tev-CAT).  The differences between 
the constructs were the origin of replication (pSC101* of 3-5 copies per cell and p15A of 
30-50 copies per cell), the TEVsh protease, and the N terminal fusion to tig144 (Figure 
 5-6).   
 
 
5.4.1 CONSTRUCTION OF THE REDESIGNED PLASMIDS 
 
The constructs were built as separate pieces of DNA via PCR (Fusion gene, 
Origin of replication p15A/pSC101*, and TEVsh/tig144TEVsh).  Different pieces of 
DNA were recombined sequentially into the destination plasmid pZS*24MCS to produce 
the four target clones (Figure  5-6). 
 
 
5.4.2 CONSTRUCTION OF THE FUSION GENE ccdB/CAT 
 
The fused gene was created as follows: briefly ccdB and CAT were amplified 
separately via Sequential PCR using Phusion™ High-Fidelity PCR (Finnzymes, MA).  
Sequential PCR was carried out as mentioned before, the PCR primers were used to add 
two tev sites (ENLFYQS), a PLtetO-1 promoter sequence (Lutz et al, 1997) and StuI 
restriction site upstream of tev site 1 (Figure  5-7).  The 15 base-overlaps the destination 
plasmid were added to the 5’ end of the promoter.  CAT was amplified via PCR with 15 
base overlaps of the tev site 2 were added to the 5’ end of CAT and 15 base overlaps in 
the destination plasmid were added to the 3’ end of CAT.  The two PCR fragments were 
gel purified and allowed to recombine using Infusion Advantage PCR cloning kit 
(Clontech, CA).  The recombination product (promoter-tev1-ccdB-tev2-CAT) was 
amplified using appropriate primers and gel purified then used for recombination with the 
target plasmid.  The target plasmid was digested by AatII/EcoRI (NEB, MA) to remove 
the plasmid’s own promoter, RBS, and MCS.  Promoter-tev1-ccdB-tev2-CAT fusion was 
recombined into the digested plasmid using Infusion Advantage PCR cloning (Clontech, 
CA).  Recombination product was transformed into electrocompetent One Shot ccdB 
Survival Cells (Invitrogen, CA) and selected on kanamicin (25µg/ml) LB agar plates.  
Clones that carried the insert were verified by PCR and sequencing.  Table  2-1 lists 
primers used for cloning under ccdB/CAT.  Figure  5-8 shows the general scheme for 
constructing all four clones. 
 
 
5.4.3 EXCHANGING pSC101* WITH p15A 
 
The pSC101* origin of replication was removed from the target plasmid via 
double digestion with AvrII/SacII-HF (NEB, MA).  The p15A origin of replication was  
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Figure  5-6  Schematic of the four clones for testing ccdB regeneration from target 
plasmid.  Green ORF represent ccdB, blue ORF represent CAT, red ORF represent 
TEVsh, tig144 is represented by gray ORFs, tetracycline promoter are represented by 
black arrow heads and ara/lac promoters are represented by gray arrow heads, Origin of 
replication is represented by black arrows. 
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Figure  5-7  Modified fusion gene including tev sites. 
 
 
 
 
 
 
 
 
 
 
 
Figure  5-8  Scheme for the construction of different target plasmids. 
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amplified by PCR using pZA24MCS as a template.  15 base overlaps between the 
amplicon and the ends of the digested plasmid were created in the same PCR.  
Recombination, transformation and selection were carried out as mentioned before; 
clones were selected and verified by PCR and DNA sequencing.  At this stage we have 
created two target plasmids (both have identical fusion genes) with a different origins of 
replication (pSC101* & p15A). Table  2-1 lists primers used for this reaction under 
“Origin Change”. 
 
 
5.4.4 INSERTION OF TEVsh AND tig144TEVsh INTO THE TARGET PLASMID 
 
Two different TEV protease constructs were created.  The first was a fusion 
between the TEVsh (van den Berg et al, 2006) and the promoter Plac/ara-1 (Lutz et al, 
1997).  As mentioned before, PCR was used to amplify each fragment.  TEVsh amplified 
from TH24 plasmid (gift from Dr Berglund) (van den Berg et al, 2006), and Plac/ara-1 was 
amplified from pZS*24MCS.  15 base overlaps were created at the points of 
recombination between both fragments i.e. the TEVsh amplicon included the translation 
signals for the gene (RBS and first ATG).  Recombination was carried out as described 
previously.  The promoter/TEVsh fusion was PCR amplified and gel purified.  The 
second TEV protease construct was composed of three pieces of DNA.  One piece 
represented the promoter Plac/ara-1 (Lutz et al, 1997), the second represented tig144 (from 
the E. coli DH5α chromosome), and the third piece represented the TEVsh gene.  PCR 
was used to amplify each fragment and to create 15 base overlaps between all fragments 
at the points where each fragment recombined with the other (Figure  5-8).  An overlap 
was created between the 3’end of the promoter and the 5’ end of tig144.  Another overlap 
was created between the 3’ end of tig144 and the 5’ end of TEVsh.  Recombination was 
carried out between all three DNA fragments, and the tripartite product was amplified by 
appropriate PCR primers and the product was gel purified.  Both TEVsh Constructs 
carried 15 bases-overlap with the destination plasmid at each end.  Both target plasmids 
were linearized by AvrII digestion and then recombined with either of the TEVsh 
constructs.  Recombination products (Figure  5-6) were subsequently transformed, 
selected and checked as before.  (Table  2-1 has the list of primers under pBAD Cloning, 
Tig144 Cloning, TEV for Tig144 Cloning, TEV for pBAD Cloning). 
 
 
5.5 OPTIMIZING THE TARGET PLASMIDS 
 
The target plasmid construction went through an optimization process.  Pieces of 
DNA were fused into the plasmid at different stages, as detailed in Figure  5-8.  
Optimizations led to the emergence of problems that were not foreseen in the original 
scheme and needed to be resolved in order for the target plasmid to be useful.   
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5.5.1 StuI RESTRICTION SITE OVERLAPPING dcm METHYLASE SITE 
 
We planned to use StuI site for insertion of the chlamydial library.  The StuI 
enzyme is sensitive to methylation.  Methylation may take place because of an 
overlapping dcm methylation site.  A dcm methylation site overlapping StuI site was 
created when tev site1 was added upstream of ccdB (AGGCCTGG the underlined 
sequence is StuI site, the 2 extra Gs after the StuI site created CmCTGG which is a dcm 
methylation site).  To make the StuI site functional, methylation was prevented by 
transforming target plasmids into the dcm deficient strain Bl21A1 E. coli (Invitrogen, 
CA).  Knowing that Bl21 was recA+/endA+ (Phue et al, 2008), we preformed an extra 
washing step during plasmid preps to remove the excess nucleases (as recommended by 
the manufacturer).  BL21 was not used for long term storage of target plasmids. 
 
 
5.5.2 REMOVAL OF StuI SITE 
 
tig144 contained an StuI site at position Q9.  In order to remove this site we 
introduced a silent mutation into Q9 as follows:  target plasmids were grown in dcm+ cells 
(TOP10, Invitrogen) and plasmids were double-digested with StuI/SalI-HF (NEB, MA).  
Under these conditions only a single StuI site (in tig144) was digested leaving the other 
methylated StuI site intact.  The double digest removed a 171 nt DNA fragment 
overlapping the junction between the promoter and tig144.  PCR was used to amplify this 
171 nt fragment and to include 15 bases-overlap with digested plasmid ends.  The reverse 
primer was used to introduce a silent mutation into tig’s Q9.  CAAggcct was mutated to 
CAGggcct; the capital letter represented the mutated codon (encodes for Q) and the 
underlined sequence represent the StuI site.  The modified DNA fragment was 
recombined into the target plasmid.  Each recombination reaction was subsequently 
transformed/selected and verified as before.  Figure  5-9B shows 2 PCR amplicons 
digested with StuI.  Lane one represented the modified tig144, lane two represented 
nonmodified tig144. The nonmodified tig144 was cleaved by StuI (small band) while the 
modified tig144 resisted StuI digestion.  (Table  2-1 has list of primers under “Tig144: 
StuI Removal”). 
 
 
5.5.3 ADDITION OF THE FIRST CODON OF ccdB AND MODIFICATION OF 
tev SITE1 
 
The translational signal of ccdB was removed during initial cloning of the fusion 
gene.  A chlamydial library inserted upstream of ccdB was planned to provide the 
translational signal.  After creating a tev cleavage site upstream of ccdB the first codon 
was no longer the first ATG of ccdB gene.  In order to make ccdB similar to the wild-type 
gene we decided to insert the first codon of ccdB.  The tev site1 in the fusion gene was 
ENLFYQS.  Cleavage occurred between Q/S leaving an S on 5’end of CcdB.  The 
polarity of Serine may have a detrimental effect on CcdB function.  We decided to mutate 
S to G as both S and G are strong cleavage sites for the TEV protease.  The target 
plasmid was digested with StuI/BmgBI.  The double digestion removed 151 nt  
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Figure  5-9  Functional analysis of target plasmids.  Panel A shows sequencial nested PCR 
that added ATG and tev cleavage sites to ccdB.  Panel B shows StuI digestion of wild-
type and modified tig144; lane 1 shows modified tig144 that is resistent to StuI digestion, 
lane 2 shows wild-type tig144 sensitive to StuI digestion.  Panel C shows Western blot 
results of TEVsh expression (the membrane was probed by anti-V5 antibody).  Lane 1 
shows TEVsh lane 2 shows tig144TEVsh fusion.  Panel D shows western blotting results 
of reporter fusion protein expression (the fusion protein was probed by anti-CAT 
antibody): lane 1 shows fusion protein not digested by TEVsh, lanes 2 to 5 show digested 
fusion protein.  The small size fragment represent CAT as seen in lanes 2 to 5, all four 
target plasmids exhibit processed fusion protein.  Panel E shows the effect of expressing 
the fusion protein with TEVsh in ccdB sensitive E. coli.  Turbid tubes represent clones 
where TEVsh expression was inhibited (no inducers) while clear tubes represent clones 
where TEVsh expression was induced. 
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piece of DNA.  overlapping ccdB 5’ half of the gene and tev site1.  Sequential PCR was 
used to amplify the 151 nt and reconstruct the tev site1 and insert ATG as codon 1 in 
ccdB gene.  The amplicon also had 15 bases-overlap with the digested plasmid.  The 
amplicon was gel purified, recombined into the plasmids transformed/selected and 
verified as before.  Figure  5-9A showed the results of the sequential PCR to create the 
modified 151 nt. 
 
 
5.6 FUNCTIONAL ANALYSIS OF TARGET PLASMIDS 
 
Target plasmids were checked for expression of TEVsh and tig144TEVsh 
proteases by Western blotting.  TEVsh gene carried a C terminal V5 epitope tag and we 
used antiV5 antibodies for detection.  Samples were grown overnight under inducing 
conditions (IPTG 1mM/Arabinose 0.2%).  Cells were collected by centrifugation and 
solubilized for gel electrophoresis.  Electrophoresis and Western blotting were carried out 
according to manufacture’s instructions (NuPage, Invitrogen).  The membrane was 
blocked overnight with nonfat dry milk and developed according to manufacturer’s 
instructions. The primary antibody used was rabbit antiV5 antibody (Abgent, CA) and the 
secondary antibody was HRP conjugated goat anti rabbit (Abcam, MA).  Bands were 
visualized by ECL reagent (Abcam, MA).  Two bands were detected (Figure  5-9C).  
Lanes 1 and 2 represented TEVsh (33.44 kDa) and tig144TEVsh (49.25 kDa) 
respectively (the brackets represent the calculated molecular weights [MW]).  The 
Western blot showed significant agreement between the calculated MWs and the 
observed ones. 
 
To verify the expression and processing of the fusion protein, the four target 
plasmids were compared to a plasmid that contained the fusion gene but did not contain 
the TEVsh protease gene.  The plasmids were digested with StuI.  PCR amplified and gel 
purified hctA leader sequence was recombined into the linearized plasmids; (Section 
 5.3.3 above).  Recombined plasmids were transformed into ccdB resistant cells and 
selected on Chloramphenicol (12.5µg/ml) LB agar plates.  Positive clones were grown 
overnight under inducing conditions (IPTG 1mM, Arabinose 0.2%) in LB broth.  Cells 
were collected by centrifugation and used for electrophoresis.  Electrophoresis and 
Western blotting were carried out according to manufacture’s instructions (NuPage, 
Invitrogen).  The membrane was blocked overnight with nonfat dry milk and developed 
according to manufacture’s instructions.  The primary antibody used was rabbit anti-CAT 
(SIGMA, MS) and the secondary antibody was HRP conjugated goat anti-rabbit (Abcam, 
MA).  Immunoreactive proteins were visualized using an ECL procedure (Abcam, MA).  
Target plasmids that did not express TEVsh protease showed the full length fusion 
protein.  The apparent size of the fusion protein agreed with the calculated size (~41.4 vs 
43.5kDa respectively, Figure  5-9D upper panel lane 1).  The four target plasmids (Figure 
 5-6) showed complete processing of the fusion protein.  The complete processing of the 
fusion protein was evident by the absence of the full length fusion-protein (upper panel 
Figure  5-9D, lanes 2-5).  Free CAT protein accumulated after digestion (lower panel 
Figure  5-9D lanes 2-5) and its apparent size was in agreement with the calculated size 
(>20.7 vs 25.49kDa).  Longer exposure time (data not shown) showed detectable 
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amounts of the unprocessed fusion protein in lanes 2 and 4 representing plasmids that 
carry TEVsh/pSC101*, TEVsh/p15A. 
 
Plasmids (TEVsh/p15A, tig144TEVsh/p15A) were selected for further analysis.  
Both plasmids were transformed into BL21A1 cells (Invitrogen, CA).  Transformed 
Bl21AI cells were grown overnight in LB under inducing (IPTG 1mM, Arabinose 0.2%) 
and non-inducing conditions.  Figure  5-9E showed the results of a 24 hour culture.  
Induced BL21 cells did not grow while uninduced cells showed growth.  These results 
confirmed that when TEVsh protein expression was induced the fusion protein was 
processed and free CcdB protein accumulated.  Free CcdB formation led to inactivation 
of GyrA and E. coli growth was inhibited. 
 
 
5.7 DISCUSSION 
 
 
5.7.1 THE USE OF ccdB AS A REPORTER GENE 
 
Initially we planned to use LacZ/CAT translational fusions to screen the 
chlamydial library for ncRNA targets.  Several investigators have used lacZ translational 
fusions to analyze ncRNA/target interactions (Baker et al, 2007; De Lay and Gottesman, 
2009; Mandin and Gottesman, 2009; Pulvermacher et al, 2009).  We did a pilot 
experiment where we inserted test sequence carrying translational signals upstream of the 
LacZ fusion gene.  The variability of the blue color (generated by X-gal) was significant 
(data not shown).  The fact that the main phenotype to determine ncRNA/target 
interactions was variable for the same insert led us to switch to an alternative plan, LacZ 
would however be used for quantification of potential interactions (β-galactosidase 
assay).  ccdB on the other hand, was used before in a limited number of applications.  
Insertional inactivation of the gene was used to select clones with DNA inserts in the 
gene (Gabant et al, 1997; Van Reeth et al, 1998).  It was also used to screen for 
mutations or inhibitors that interfere with protein splicing mediated by the RecA intein of 
Mycobacterium tuberculosis.  This screening procedure involved activation of the CcdB 
protein by protein splicing, such that host cells survive in the presence of inducer only 
when protein splicing was blocked (Lew and Paulus, 2002).  CcdB is also used as a 
general selection marker in the gateway system (Invitrogen, CA).  Clones that fail to 
undergo recombination and exchange the ccdB cassette with the insert do not survive 
CcdB mediated killing.  CcdB produced a criterion phenotype that is clear cut i.e. cell 
death.  A great deal is known about its function and it’s crystal structure has been 
published (Dao-Thi et al, 2004; Dao-Thi et al, 1998; Loris et al, 1999).  Moreover there 
is an E. coli strain that is resistant to CcdB mediated killing (Bernard et al, 1992). 
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5.7.2 CcdB LOSS OF FUNCTION AND REDSIGNING OF THE TARGET 
PLASMID 
 
ccdB fusions are not commonly used in molecular biology.  The single fusion that 
was reported was a lacZ N-terminal fusion to ccdB (Bernard, 1996; Gabant et al, 1997).  
Personal communications with Paulus H (Lew et al, 2002) (Personal communications, 
2009) revealed that CcdB lost its lethal effect when 25 or more amino acid residues were 
fused to the N terminus.  In this work we have presented the results of C terminal fusions.  
We have tried N terminal fusions (data not shown), but this construct was very toxic and 
we were not able to maintain an intact plasmid within the ccdB resistant cells.  The 
plasmid instability forced us to use C terminal fusions.  CcdB in C-terminal fusion lost its 
lethal effect.  We shifted our plan to insert protease cleavage sites flanking ccdB so that 
we regenerate a CcdB protein molecule similar to wild-type. 
 
The loss of a lethal effect with CcdB-CAT fusions led us to propose that the C 
terminal fusion to CcdB causes loss of activity.  Bahassi et al. studied CcdB loss of 
function mutants and found seven mutations in CcdB 3’ end that had no lethal effects.  
The mutations were all in the last 3 amino acids of the molecule (Bahassi et al, 1995).  
This finding suggested that the C terminal domain of the molecule was important for 
function and that C terminal fusions might not function properly.  Dao-Thi et al. analyzed 
the crystal structure of CcdB bound to GyrA peptide (Dao-Thi et al, 2005) and showed 
that CcdB W99 (CcdB has 102 amino acids total) interacted with GyrA462R.  Mutations 
in either of these two interacting amino acids led to loss of function for CcdB.  Finally, 
ccdB resistant cells have an identical mutation in GyrA (gyrAR462C).   
 
In light of the previous argument, we reasoned that any deviation from wild-type 
CcdB might be detrimental to its function.  Dao-Thi et al. shown that CcdB functions as a 
dimer.  For dimerization to occur hydrophobic interactions between 6 methionines was 
required (Dao-Thi et al, 2005).  Although the first methionine was not included in the 
interaction, we chose to re-insert M1.  After TEV protease cleavage, the only residue that 
was left on the N terminus was S (or G).  We chose to mutate S to G to eliminate a 
potential source of increased polarity in the region. 
 
We designed four target plasmids.  We reasoned that screening of chlamydial 
libraries will result in cloning many chlamydial translational signals with wide range of 
activities.  The target plasmids therefore were designed with different copy number 
controlling regions to cover the spectrum of translational strength.  Two different origins 
of replication were used.  We also used two TEV protease constructs with different 
proteolytic efficacy that allowed us to control the amount of available CcdB protein 
within a cell.  Although the Western blotting results does not show differences in efficacy 
of TEV cleavage (Figure  5-9D, lanes 2-5), over exposure showed traces of undigested 
fusion protein in clones carrying TEVsh (lane 2, 4).  Total digestion of the fusion protein 
was evident for clones having tig144TEVsh (lane 3, 5).  This result is in complete 
agreement with Henrichs et al, 2005. 
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CHAPTER 6.   CONCLUDING REMARKS 
 
 
C. trachomatis D/UW-3/Cx expresses numerous ncRNAs that were initially 
detected using an intergenic microarray and validated by Northern blotting analyses.  
These include the subset of potential ncRNAs in this study which are potential cis-acting 
(antisense), trans-acting, and riboswitches.  We have shown that these ncRNAs have 
distinct temporal expression patterns during the normal developmental cycle and several 
appear to be processed.  We have also shown that the expression of many ncRNAs was 
altered during growth conditions that induce persistent growth, particularly IFN-γ-
induced persistence and carbenicillin-induced-persistence.  We have mapped the ends of 
these ncRNAs, a prerequisite for cloning and functional analysis of these molecules.  We 
have developed a system for testing cis-acting ncRNAs, and successfully used it for 
verification of the proposed function of CTIG270.  We have also developed a screening 
system for trans-acting ncRNAs: a system based on positive/negative selection that is 
fully functional in E. coli.  We believe that this screening tool can also be used to screen 
for ncRNA targets in other organisms.   
 
Although these studies in C. trachomatis are primarily associated with the 
discovery and validation phase for ncRNAs, they provide a strong basis for mechanistic 
studies that may determine important regulatory roles for chlamydial ncRNAs in the 
development cycle and the changes that occur during persistent growth of C. trachomatis. 
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